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ABSTRACT 
Sungkyoon Kim 
Benzene Metabolism in Humans: Dose-dependent Metabolism  
and Interindividual Variability 
(Under the direction of Prof. Stephen M. Rappaport) 
 
In order to gain a better understanding of dose-dependant metabolism of benzene and 
interindividual variation, we analyzed air benzene, urinary metabolites and personal 
information, including single nucleotide polymorphisms of key metabolic enzymes, from 389 
subjects exposed to benzene occupationally/environmentally. The apparent levels of benzene 
metabolites increased with exposure, and levels of benzene metabolites were unambiguously 
different from background levels at: ~ 0.2 ppm for E,E-muconic acid (MA) and S-
phenylmercapturic acid (SPMA), ~ 0.5 ppm for phenol (PH) and hydroquinone (HQ), and ~2 
ppm for catechol (CA). After adjustment for the background levels, MA, PH, CA and HQ 
showed significant (p<0.001) downward trends of dose-related production between 0.027 
and 15.4 ppm. The transitions were particularly accentuated at lower exposure (0.027 and 
0.274 ppm) for all metabolites. These were confirmed with generalized linear models with 
natural splines (GLM+NS). Based on analysis using the molar fraction, CYP-mediated 
metabolic pathways favored MA and HQ below 20 ppm and favored PH and CA above 20 
ppm. Noticeably, ~90% of the reductions in dose-specific levels occurred below ~3 ppm for 
each major metabolite. Metabolite levels were about 20% higher in females and decreased 
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between one and 2% per year of life.  Also, levels of HQ and CA were greater in smokers. 
After adjustment for age, gender, BMI and smoking status, the following SNPs showed 
significant effect on various metabolites, either as main effects or as interactions with 
benzene exposure and/or smoking: NQO1*2 for all metabolites, CYP2E1 for all metabolites 
except CA, GSTT1 and GSTM1 for SPMA, EPHX1 (Ex4+52A>G) for SPMA and CA, and 
EPHX1 (Ex3-28T>C) for CA.  Interestingly, variant alleles of all genes [except EPHX1 
(Ex4+52A>G)] appeared to be associated with lower levels of benzene metabolites relative 
to homozygous wild alleles. In conclusion, our results indicate that benzene metabolism is 
highly nonlinear with increasing benzene exposure above 0.03 ppm, and that metabolism 
shifts away from CA and PH at low doses in favor of MA and HQ. Also, metabolism of 
benzene is modulated by exposure, gender, age, smoking, and genetic polymorphisms. 
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CHAPTER 1.   
GENERAL INTRODUCTION 
 
Benzene is a useful industrial chemical and is ubiquitous in the environment. It is an 
established human carcinogen (IARC, 1982; Wallace, 1996; ATSDR, 1997; NICNAS, 2001). 
Since early reports on benzene-induced hematotoxicities (Vigliani and Saita, 1964; Snyder, 
2002), many studies have been carried out in the fields of epidemiology and exposure 
assessment. However, the mechanisms of hematotoxic effects and the shape of the exposure-
response relationships [in particular below 1 ppm] are still controversial (Rothman et al., 
1996a; Savitz and Andrews, 1997; Ross, 2000; Snyder, 2000a; Snyder, 2002; Glass et al., 
2003; Lan et al., 2004; Schnatter et al., 2005). The present study is focused on these issues to 
provide a better understanding of human benzene metabolism, specifically, dose-dependant 
metabolic profiles of benzene and possible genetic predispositions involving benzene 
metabolism. 
 
1.1. Exposure to Benzene 
Benzene exposure occurs both in the workplace and the general environment. In the 
workplace, benzene is used primarily as an intermediate in production of Styrofoam, other 
plastics, synthetics and fibers.  It is also an important raw material and excellent solvent for 
synthetic rubbers, lubricants, dyes, pharmaceuticals and pesticides (ATSDR, 2000). Strict 
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regulation of benzene exposure has been increasingly required due to the observed risks of 
exposure to benzene in occupational studies (ATSDR, 2000; ACGIH, 2004). The current 
permissible exposure limit (PEL) set by US OSHA is 1.0 ppm (OSHA, 1987) and the 
ACGIH threshold limit value (TLV) is 0.5 ppm (ACGIH, 2004).  Environmental sources of 
benzene exposure are industrial pollution, automobile fuel and combustion products, and 
cigarette smoking.  Ambient outdoor air levels of benzene globally are around 2 parts per 
billion (ppb) on average (range 0.6–3 ppb) (ATSDR, 1997). Smokers consuming a pack of 
cigarettes per day inhale a daily dose of approximately 1 mg of benzene, about 3 to 4% of the 
amount inhaled daily by a worker exposed at 1 ppm. Passive smokers typically have 50% 
greater exposure to benzene than nonsmokers (Wallace, 1996).  Potential leakage from 
underground storage tanks and landfills and improper disposal of wastes can lead to benzene 
exposure via drinking water. Drinking water typically contains less than 0.1 ppb benzene. 
There have been reports that benzene has been detected at trace levels in bottled water, 
liquor, and food (ATSDR, 1997). 
1.2. Health Effects of Benzene in Humans 
While acute exposure to very high levels of benzene, occurring accidentally, can lead to 
death, depression of the central nervous system (CNS) or irritation, such situations are rare. 
Long-term chronic exposures are much more common, and can induce irreversibly fatal 
effects including leukemia (ATSDR, 1997; EPA, 2002). Hence, we focus on the chronic 
exposures to benzene. 
1.2.1. Hematopoietic Toxicity  
Exposure to excessive concentrations of benzene can induce bone marrow depression, 
which leads to reduction in blood cells and aplastic anemia (Aksoy, 1989; Rothman et al., 
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1996a; Rothman et al., 1996b; Hayes et al., 1997; Snyder, 2002). Several mechanisms have 
been suggested to explain benzene-induced hematotoxicity, such as direct toxicity to 
hematopoietic progenitor cells by reactive benzene metabolites (Irons and Neptun, 1980; 
Chen et al., 1994; Smith et al., 2000; Zhang et al., 2002), impairment of the bone marrow 
stromal microenvironment (Longacre et al., 1981; Garnett et al., 1983; Gaido and Wierda, 
1985; Thomas et al., 1990), and inhibition or alteration of regulatory cytokines produced by 
marrow cells (Miller et al., 1994; Kalf et al., 1996; Ross et al., 1996).  
Repeated benzene exposure at higher levels has been associated with benzene poisoning 
(Aksoy et al., 1971; Midzenski et al., 1992; Rothman et al., 1996a; Rothman et al., 1996b). 
Symptoms of benzene poisoning include decreased numbers of lymphocytes, white blood 
cells, red blood cells, platelets, hemoglobin and hematocrit, and an increase in the mean 
corpuscular volume (MCV) (Rothman et al., 1996a). Dosemeci et al. showed a clear dose-
response relationship between benzene exposure and benzene poisoning (Dosemeci et al., 
1997), and Rothman et al. reported  that benzene poisoning was strongly associated with 
myelodysplastic syndrome (MDS) and/or acute myelocytic leukemia (AML) with a 71-fold 
higher risk (95% CI, 11–439) relative to controls without benzene poisoning (Rothman et al., 
1997).  
1.2.2. Genotoxicity and Leukemia 
Benzene metabolites can give rise to DNA damage, subsequent translocations, or other 
insults associated with inhibition of topoisomerase II. 1,4-benzoquinone (BQ), a metabolite 
of benzene, was suggested to bind to guanine or adenine residues, and inhibit 
mRNA(Rushmore et al., 1984). It has also been suggested that E,E-Muconaldehyde (MUC), 
the ring opening product of benzene, could bind to DNA by forming DNA-protein cross links 
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(Schoenfeld and Witz, 1999). Interestingly, DNA adducts appear to be minor products of 
benzene metabolism with uncertain health implications (Subrahmanyam et al., 1991) (Creek 
et al., 1997; Snyder, 2002). Benzene exposure unequivocally produces chromosome 
aberrations (Tough and Brown, 1965; Tough et al., 1970; Forni, 1996).  High exposure to 
benzene (+31 ppm) can cause aneuploidy, long-arm deletions and translocations in 
chromosomes 1, 5, 7, 8 9 and 21 (Rothman et al., 1996b; Zhang et al., 1996; Smith et al., 
1998; Zhang et al., 1998) and gene duplication in nucleated erythrocyte stem cells at the 
glycophorin A locus on chromosome 4 (Rothman et al., 1995).  It appears that benzene-
induced chromosome aberrations are important to benzene-induced leukemia (Zhang et al., 
2002). Using CD34+, a surface antigen found in pluripotent stem cells or early progenitor 
cells in bone marrow, the benzene metabolite, hydroquinone (HQ) induced more aneusomy 
in CD34+ carrying cells on chromosomes 7 and 8, which are consistent with findings in 
myeloid leukemia (Smith et al., 2000).   
Since early reports on benzene-induced leukemia (Vigliani and Forni, 1969; Aksoy et 
al., 1971; Vigliani and Forni, 1976), numerous epidemiologic studies have shown 
associations between benzene exposure and leukemia (Snyder, 2002). In the Pliofilm cohort 
studies, the standardized mortality ratio (SMR) was 560 for the exposed group at large, and 
projected SMR for excess of leukemia was 109-6637 at 40-400 ppm-year (Rinsky et al., 
1981; Rinsky et al., 1987). However, there were controversies regarding the exposure-
estimates used in those studies (Kipen et al., 1988; Kipen et al., 1989; Paustenbach et al., 
1992; Cody et al., 1993; Paxton et al., 1994; Utterback and Rinsky, 1995; Crump, 1996). The 
Chinese cohort studies, which recruited much larger number of subjects, showed clear 
evidence of significantly increased risks for AML, MDS, and aplastic anemia (Yin et al., 
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1996). In the extended Chinese cohort study, acute nonlymphocytic leukemia (ANLL [or 
AML] ) or MDS was found to be associated with recent exposure (<10 year prior to 
diagnosis) (Hayes et al., 1997). A dose-response relationships was demonstrated between 
cumulative exposures to benzene and a spectrum of blood cancers and blood disorders, with 
increased risks at <40 ppm-yr. Relative risks for ANLL/MDS or other blood cancers were 
more than doubled with average exposures of about 10 ppm.  Although there are further 
controversies regarding exposure estimates from the Chinese study (Dosemeci et al., 1997; 
Schnatter et al., 2005), these results suggest the possibility of an increased risk of leukemia 
below the levels of exposure suggested by the earlier Pliofilm cohort.  As such, benzene is 
widely accepted as a leukemogen (primarily for AML) (IARC, 1982; ATSDR, 1997; EPA, 
1998). Furthermore, we cannot exclude the linkage of benzene exposure to other leukemias 
(Savitz and Andrews, 1997) such as acute and chronic lymphocytic and myeloid leukemia 
(Hayes et al., 1997; O'Connor et al., 1999; Wong and Raabe, 2000; Hayes et al., 2001; 
Schnatter et al., 2005).  It has recently been shown that cumulative exposures as low as 8 
ppm-years have resulted in significantly increased leukemia risks  (Glass et al., 2003).   
The mechanisms of leukemogenesis and benzene induced toxicities are not yet fully 
understood. Given that benzene metabolites can cause DNA damage, aneusomy or other 
insults (e.g. associated with inhibition of topoisomerase II), benzene metabolites can be 
termed as initiators. Also they can induce expansion of a less differentiated pool of myeloid 
cells, which is a property of a promoter (Snyder, 2000b; Snyder, 2000a). One suggested 
mechanism for benzene-induced leukemia is depicted in Fig. 1.1.  
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Figure 1. 1. Postulated processes of benzene-induced leukemia (modified from (Snyder, 
2000b)). Legends: ROS, reactive oxygen species; HQ, hydroquinone. 
 
1.2.3. Other Effects 
Several reports have linked benzene exposure to a host of other effects (ATSDR, 1997) 
including  menstruation disorders (Dahl et al., 1999), spontaneous abortions (Xu et al., 
1998), melanoma, breast cancer (Petralia et al., 1999) and childhood leukemia (Pearson et 
al., 2000; Zeise and McDonald, 2000). However, causal relationships between exposure and 
these effects have not been established due to co-exposures to other xenobiotics and 
inconsistent results among studies (NICNAS, 2001).  
 
1.3. Metabolism of Benzene 
1.3.1. General Pathways of Benzene Metabolism 
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While it is generally accepted that benzene causes toxic effects via metabolism, the 
particular toxic metabolite(s) remains elusive (Snyder and Hedli, 1996; Snyder, 2000b).  The 
major metabolic pathways are shown in Figure 1.2.  Benzene is metabolized by cytochrome 
P450 (CYP) enzymes (primarily CYP2E1) to benzene oxide (BO, which is in equilibrium 
with its tautomer, oxepin), an electrophile that binds to macromolecules (Lindstrom et al., 
1998; Lindstrom et al., 1999; Yeowell-O'Connell et al., 2001; Rappaport et al., 2002) and is 
the source of all other metabolites.  Spontaneous rearrangement of BO produces phenol (PH) 
(Jerina and Daly, 1974), which can undergo another CYP oxidation to give hydroquinone 
(HQ)(Koop et al., 1989; Valentine et al., 1996).  Hydrolysis of BO via epoxide hydrolase 
(EPHX1) produces benzene dihydrodiol which can be converted to catechol (CA), via 
dihydrodiol dehydrogenases, or to benzene diolepoxides via CYP oxidation(Bolcsak and 
Nerland, 1983).  Hydroquinone and CA can be oxidized to 1,4-BQ and 1,2-BQ, respectively, 
which also bind to macromolecules (McDonald et al., 1993; Waidyanatha et al., 1998; 
Yeowell-O'Connell et al., 2001). A second CYP oxidation of oxepin, followed by ring 
opening, produces the muconaldehydes (MUC) (Witz et al., 1996).  These reactive species 
are also capable of binding to macromolecules (Golding and Watson, 1999; Amin and Witz, 
2001; Oshiro et al., 2001) and are ultimately converted to E,E-muconic acid (MA) (Snyder 
and Hedli, 1996; Scherer et al., 1998). The major phenolic metabolites, i.e., PH, HQ, and 
CA, are easily conjugated and excreted in urine (Sabourin et al., 1989; Seaton et al., 1995; 
Snyder, 2004).  Minor pathways of benzene metabolism include S-phenylmercapturic acid 
(SPMA) following reaction of BO with glutathione, supposedly via glutathione S-transferase 
(GST) (Boogaard and van Sittert, 1996; Henderson et al., 2005a), and 1,2,4-
trihydroxybenzene via CYP oxidation of HQ(Rushmore et al., 1984; Ross, 2000).  Of all the 
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benzene metabolites, 1,4-benzoquinone (derived from HQ) has most often been linked to the 
spectrum of toxic effects observed in humans and animals (Smith, 1999; Snyder, 2000a; 
Snyder, 2000b; Inayat-Hussain and Ross, 2005).   
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Figure 1. 2. Simplified metabolic scheme for benzene showing major pathways and 
metabolizing genes. 
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1.3.2. Toxicological Overview of Benzene Metabolites 
As described earlier, there is no doubt that benzene must be metabolized in the liver 
before causing adverse effects on bone marrow depression. However, it has not been clearly 
determined (Snyder, 2002) whether the benzene metabolites from hepatic metabolism induce 
bone marrow depression, and if so, what the toxicological mechanism would be. Also, the 
role(s) that might be played by polymorphisms of metabolizing enzymes on susceptibility to 
benzene-induced toxicity (and/or metabolism) has not been established. Here, we provide a 
brief overview of benzene metabolism from a toxicological point of view.  
It has been reported that a combination of benzene metabolites is needed to induce 
benzene toxicity in animal and human cells in vitro (Eastmond et al., 1987; Snyder et al., 
1989; Subrahmanyam et al., 1989; Subrahmanyam et al., 1990; Levay and Bodell, 1992; 
Marrazzini et al., 1994; Ross, 2000; Snyder, 2004). Specifically, Snyder et al. reported that 
the potency of metabolites (or their binary combinations) as potential inhibitors of 
erythropoesis in mice increased in the following order: HQ-sulfate < HQ < CA < 6-OH-tt-
2,4-hexadienal < HQ + PH < PH < CA+ PH < 1,4-BQ < MUC <  MUC + HQ (Snyder et al., 
1989; Snyder, 2004). 
Numerous studies have showed that HQ and CA are further metabolized by 
myeloperoxidase (MPO) or prostaglandin H synthase to form semiquinones or 
benzoquinones, which can bind to macromolecules in bone marrow or blood (Post et al., 
1986; Bhat et al., 1988; Schlosser and Kalf, 1989; Subrahmanyam et al., 1989; 
Subrahmanyam et al., 1990). Given more abundant MPO in bone marrow than in liver, it has
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been speculated that activation of  HQ and CA to toxic quinones is more likely in bone 
marrow than human liver (Snyder, 2002).  
In addition to further metabolism of HQ, the oxygen stress from redox cycling or 
autooxidation can convert molecular oxygen into the superoxide anion, which is then 
converted to hydrogen peroxide, and the very reactive hydroxyl radical. These reactive 
oxygen species (ROS) damage proteins, DNA bases, structural chromosomes, lipid 
membranes, etc. (NICNAS, 2001). While redox cycling among HQ, 1,4-semiquinone, and 
1,4-BQ can also generate ROS, it is unlikely at physiological pH owing to protonation of the 
semiquinone, thus limiting superoxide production (Boersma et al., 1994). Alternatively, 
Brunmark et al. suggested autooxidation as an alternative source of ROS (Brunmark and 
Cadenas, 1988).  The proposed mechanism proceeds as follows: 1,4-BQ is converted to an 
epoxide (2,3-epoxy-1,4-BQ), and subsequently, via reaction with glutathione, to glutathinoyl-
2,3,5-trihydroxybenzene, a species which is predisposed to autooxidize and participate in 
redox cycling by generating superoxide anions.  
Despite the lack of an animal model for benzene-induced leukemia (Snyder, 2004), the 
metabolism of benzene in mammals has been accepted to be qualitatively similar to that in 
humans (Henderson, 1996). Among mammalian species, mice are more susceptibile to 
benzene-induced toxicity than rats, and mice have more HQ in urine than rats at a same 
benzene exposure (Sabourin et al., 1987; Sabourin et al., 1988; Sabourin et al., 1992). Also, 
mice produce proportionally much more MA at low doses than at high doses (Witz et al., 
1990). Sabourin et al. demonstrated that proportionally more MA and HQ were generated at 
lower doses in several rodent species, particularly mice. The dose-dependant shift of 
metabolites, which favors MA and HQ at lower exposure to benzene, has also been suggested 
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in humans based upon studies of occupational exposures in China (Rothman et al., 1998; 
Waidyanatha et al., 2001; Melikian et al., 2002; Waidyanatha et al., 2004).  
 
1.3.3. Genetic Polymorphisms of Metabolic Enzymes 
The dose of a benzene metabolites at the target organ should depend on the level of 
metabolic enzyme in the liver (Snyder, 2002). Therefore, considering benzene-induced 
toxicity, we need to verify the role of key metabolic enzymes such as CYP (in particular 
CYP2E1), GSTs, EPHX1, dihydrodiol dehydrogenase, NAD(P)H: quinone Oxidoreductase 
(NQO1), peroxidases (notably myeloperoxidase (MPO)) (Fig. 1.2) (Note: Sulfotransferase 
and glucuronyl transferase are also important detoxifying enzymes for PH, CA, and HQ. 
Since we do not focus on the potential roles of  those conjugates in this study, we report 
levels of total phenolic metabolites (combined amounts with the free and conjugated forms).   
The phase-I enzyme CYP2E1 has been established as a primary metabolic enzyme for 
benzene (Seaton et al., 1994; Valentine et al., 1996; Nedelcheva et al., 1999) forming BO 
and subsequently PH and HQ (see Fig. 1.2). According to Seaton et al., the interindividual 
difference in CYP2E1 activity (determined by hydroxylation of p-nitrophenol) varied by 13-fold 
(Seaton et al., 1994) in human liver specimens. The distribution of genetic polymorphisms 
was different by races (Kato et al., 1992).  While in vitro studies showed a reduction in 
transcriptional activity of the gene (Hayashi et al., 1991), the effect of functionality and 
genotypes have not be established (Bolt et al., 2003). Although results among studies have 
been observed regarding the functionality of CYP2E1 (Lucas et al., 1995; Carriere et al., 
1996; Kim et al., 1996; Rothman et al., 1997; Nedelcheva et al., 1999; Wang et al., 1999; 
Wormhoudt et al., 1999; Carere et al., 2002) (Ingelman-Sundberg et al., 2006) (Seaton et al., 
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1994; Seaton et al., 1995), a recent in vivo pharmacokinetic study demonstrated that variant 
CYP2E1 (RsaI) caused less activity than wild-type CYP2E1 (Le Marchand et al., 2002). 
GSTs promote the reaction of  glutathione with electrophilic benzene metabolites (in 
particular, BO, MUC, and the benzoquinones) (Jerina and Daly, 1974; Goon et al., 1993). 
Several studies showed that variant forms of GSTs caused benzene-induced toxicities (Hsieh 
et al., 1999; Morgan and Smith, 2002; Dirksen et al., 2004; Kim et al., 2004). There have 
also been suggestions that GST polymorphisms are associated with increased risks of 
oxidative stress (Hayes et al., 2005). 
The EPHX1 gene catalyzes hydrolysis of arene epoxides or other reactive aliphatic 
metabolites (usually produced by CYP) into dihydrodiol derivatives (Morisseau and 
Hammock, 2005). According to a recent study using EPHX1-deficient mice, EPHX1 seems 
to be an important detoxifying enzyme in male mice (Bauer et al., 2003a). There have been 
reports of an 8-fold difference in the enzymatic activity (determined by levels of a 
benzo[a]pyrene metabolite in liver biopsy specimens) among 40 human subjects (Hassett et 
al., 1997).  
NQO1 catalyzes various substrates such as quinones via the two- or four-election 
reduction (Nebert et al., 2002), and thereby can retain quinones in their reduced and nontoxic 
forms.  Among the polymorphisms of NQO1 (Nebert et al., 2002), NQO1*2 was investigated 
extensively (Traver et al., 1997; Siegel et al., 1999; Ross et al., 2000). Recent data suggest 
that active forms of NQO1 protect against benzene-induced toxicities (Rothman et al., 1997; 
Long et al., 2002; Bauer et al., 2003b), and a high ratio of MPO to NQO1 in bone marrow 
has been suggested to confer more susceptibility to cellular damage (Ganousis et al., 1992; 
Ross et al., 1996; Ross, 2005). NQO1 can be highly inducible by electrophiles and oxidative 
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stress (De Long et al., 1987; Moran et al., 1999; Ross, 2005), and functions as a superoxide 
scavenger (Thor et al., 1982; Ross, 2005). 
 
1.4. Research Aims of this Project 
Since the risks of hematotoxicity and leukemia are thought to arise from human 
metabolism of benzene, it is important that the dose-related production of benzene 
metabolites be understood.  According to several recent studies (Rothman et al., 1998; 
Waidyanatha et al., 2001; Melikian et al., 2002), benzene metabolism appears to be  dose-
dependant. These studies had several limitations including the followings: insufficient 
sample size, no adjustment of background metabolites of benzene, no measurement of air 
exposure for control subjects, incomplete coverage of all key metabolites of benzene, limited 
consideration of factors influencing inter-individual variability (e.g. life style, metabolic 
polymorphisms, etc).  
In chapter 2 we discuss dose-related patterns of human benzene metabolism using 
urinary biomarkers. Here, we group subjects by the levels of benzene exposure and aggregate 
metabolite levels in these groups using empirical (non-parametric) analysis after adjusting for 
background levels of benzene metabolites. Then, we determine the uncertainty from the 
estimates of environmental exposure using a boot-strapping technique.   
In chapter 3, we construct a parametric model for metabolism of benzene in humans 
exposed to benzene both occupationally and environmentally. The model explains the dose-
specific productions of metabolites more extensively while addressing nonlinear relationship 
between benzene exposure and urinary metabolites of benzene. Effects of covariates (other 
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than metabolic polymorphisms) on benzene metabolites are also tested. Then, we use boot-
strapping to determine the uncertainties in estimated dose-metabolite models. 
In chapter 4, we extend the models used in chapter 3 to evaluate effects of genetic 
polymorphisms of metabolic enzymes. Thus, the enhanced models include nonlinear effects 
of benzene exposure, life-style factors, single nucleotide polymorphisms (SNP) of the key 
enzymes for benzene metabolism, and two-way interactions between SNPs and exposure or 
smoking.  
 
  
CHAPTER 2.   
USING URINARY BIOMARKERS TO ELUCIDATE 
DOSE-RELATED PATTERNS OF HUMAN BENZENE 
METABOLISM 
[Kim S, Vermeulen R, Waidyanatha S, Johnson AB, Lan Q, Rothman N, et 
al. Carcinogenesis 2006;27:772-781.] 
 
 
2.1. Abstract 
Although the toxicity of benzene has been linked to its metabolism, the dose-related 
production of metabolites is not well understood in humans, particularly at low levels of 
exposure.  We investigated unmetabolized benzene in urine (UBz) and all major urinary 
metabolites [phenol (PH), E,E-muconic acid (MA), hydroquinone (HQ), and catechol (CA)] 
as well as the minor metabolite, S-phenylmercapturic acid (SPMA), in 250 benzene-exposed 
workers and 139 control workers in Tianjin, China.  Median levels of benzene exposure were 
about 1.2 ppm for exposed workers (interquartile range: 0.53–3.34 ppm) and 0.005 ppm for 
control workers (interquartile range: 0.002 – 0.007 ppm).  (Exposures of control workers to 
benzene were predicted from levels of benzene in their urine).  Metabolite production was 
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investigated among groups of 30 workers aggregated by their benzene exposures.  We found 
that the urine concentration of each metabolite was consistently elevated when the group’s 
median benzene exposure was at or above the following air concentrations: 0.2 ppm for MA 
and SPMA, 0.5 ppm for PH and HQ, and 2 ppm for CA.  Dose-related production of the 4 
major metabolites and total metabolites (µmol/l per ppm benzene) declined between 2.5 and 
26 fold as group median benzene exposures increased between 0.027 and 15.4 ppm.  
Reductions in metabolite production were most pronounced for CA and PH below one ppm, 
indicating that metabolism favored production of the toxic metabolites, HQ and MA, at low 
exposures.   
 
2.2. Introduction 
Benzene is an important industrial chemical that is also emitted into the air from 
gasoline, engine exhausts, and combustion of organic materials (including cigarette smoke) 
(IARC, 1987; Wallace, 1996).  Occupational exposures to benzene at air levels greater than 
about 10 ppm, have long been linked to hematotoxicity and to acute myelogenous leukemia 
(IARC, 1982; Hayes et al., 1997; Savitz and Andrews, 1997).  A recent report of hematotoxic 
effects in workers exposed to benzene below one ppm (Lan et al., 2004) has raised additional 
concerns regarding the health consequences of low exposures to this contaminant.   
While it is generally accepted that benzene causes toxic effects via metabolism, the 
particular toxic metabolite(s) remains elusive(Snyder, 2000a).  The major metabolic 
pathways are shown in Figure 2.1.  Benzene is metabolized by CYP enzymes (primarily 
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CYP2E1) to benzene oxide (BO, which is in equilibrium with its tautomer, oxepin), an 
electrophile that binds to macromolecules (Lindstrom et al., 1998; Lindstrom et al., 1999; 
Yeowell-O'Connell et al., 2001; Rappaport et al., 2002) and is the source of all other 
metabolites.  Spontaneous rearrangement of BO produces phenol (PH), which can undergo  
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Figure 2.1. Simplified metabolic scheme for benzene showing major pathways. 
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another CYP oxidation to give hydroquinone (HQ).  Hydrolysis of BO via epoxide 
hydrolase produces benzene dihydrodiol which can be converted to catechol (CA), via 
dihydrodiol dehydrogenases, or to benzene diolepoxides via CYP oxidation.  Hydroquinone 
and CA can be oxidized to 1,4-benzoquinone and 1,2-benzoquinone, respectively, which also 
bind to macromolecules (McDonald et al., 1993; Waidyanatha et al., 1998; Yeowell-
O'Connell et al., 2001).  A second CYP oxidation of oxepin, followed by ring opening, 
produces the muconaldehydes.  These reactive species are also capable of binding to 
macromolecules (Golding and Watson, 1999; Amin and Witz, 2001; Oshiro et al., 2001; 
Henderson et al., 2005b) and are ultimately converted to E,E-muconic acid (MA) (Snyder 
and Hedli, 1996). The major phenolic metabolites, i.e., PH, HQ, and CA are easily 
conjugated and excreted in urine (Sabourin et al., 1989; Kenyon et al., 1995; Seaton et al., 
1995).  Minor pathways of benzene metabolism include S-phenylmercapturic acid (SPMA) 
following reaction of BO with glutathione (Henderson et al., 2005a), and 1,2,4-
trihydroxybenzene via CYP oxidation of HQ.  Of all the benzene metabolites, 1,4-
benzoquinone (derived from HQ) has most often been linked to the spectrum of toxic effects 
observed in humans and animals (Smith, 1996; Snyder, 2000a; Snyder, 2000b; Inayat-
Hussain and Ross, 2005).   
Since risks of hematotoxicity and leukemia are thought to arise from benzene 
metabolism, it is important that the dose-related production of benzene metabolites be 
understood.  Two recent studies have reported levels of urinary metabolites in both benzene-
exposed workers and control workers in China (Rothman et al., 1998; Qu et al., 2000; 
Waidyanatha et al., 2001; Melikian et al., 2002).  Metabolite profiles from those studies 
suggested shifts among the competing metabolic pathways at increasing levels of benzene 
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exposure.  The Chinese studies also pointed to relatively high levels of the phenolic 
metabolites, PH, CA and HQ in control workers, presumably from dietary and endogenous 
sources of these compounds.  These background levels of metabolites tend to obscure the 
amounts of PH, CA and HQ derived from ambient benzene exposure and from cigarette 
consumption.  Also, because benzene air concentrations levels were not reported for control 
subjects in previous Chinese studies, they could not be used to determine the utility of the 
various metabolites as biomarkers of exposure to benzene at environmental levels.   
In the present study we report levels of benzene in air and urine, as well as urinary levels 
of PH, CA, HQ, MA and SPMA, among 389 subjects (250 exposed and 139 controls) in a 
Chinese population that has shown evidence of hematotoxic effects (Lan et al., 2004).  
Because some personal measurements of airborne benzene were below the limits of detection 
(LOD) or were missing, we predict benzene exposures in these (mostly control) subjects 
from the levels of unmetabolized benzene in urine (UBz).  Then, we use the data to 
characterize relationships between metabolite levels and benzene exposures in groups of 
subjects stratified by exposure level.  This analysis identifies useful ranges of the various 
metabolites as biomarkers of benzene exposure.  Finally, we estimate the dose-related 
production of each metabolite (M urine per ppm benzene) after adjusting for background 
levels. 
 
2.3. Materials and Methods 
2.3.1. Chemicals 
Benzene, CA (99%) and HQ (>99%) were obtained from Fluka Chemical Co. 
(Switzerland). NaCl was purchased from Fisher Scientific (Pittsburg, PA) and was heated at 
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120ºC overnight prior to use. PH (99%+, redistilled), MA (98%), and [2H6]benzene (99.86%) 
were obtained from Aldrich Chemical (Milwaukee, WI). [13C6]PH (99%) and [2H6]CA (98%) 
were purchased from Cambridge Isotope Laboratories (Woburn, MA). Phenylmercapturic 
acid, Tri-Sil reagent, and concentrated hydrochloric acid (Optima grade) were purchased 
from TCI America (Portland, OR), Pierce (Rockford, IL), and Fisher Scientific (Pittsburgh, 
PA), respectively. Ethyl acetate (analytical reagent grade) and hexane (nanograde) were 
obtained from Mallinckrodt Baker (Paris, KT). Anhydrous Na2SO4 was purchased from J.T. 
Baker (Phillipsburg, NJ). 2,5-[13C2]MA, [2H5]SPMA and [13C6]HQ were kindly provided by 
Drs. Avram Gold, Ramiah Sangaiah and Alistair Henderson from the University of North 
Carolina at Chapel Hill. All headspace solid phase microextraction (HS-SPME) supplies 
were obtained from Supelco (Bellefonte, PA). 
2.3.2. Subject Recruitment and Sample Collection 
Subjects (n = 390) were recruited with informed consent from five factories in Tianjin, 
China.  Exposed subjects (n = 250) worked in two shoe-making factories, and control 
subjects (n = 140) worked in three clothes-manufacturing factories as previously described 
(Lan et al., 2004; Vermeulen et al., 2004). The eligibility and exclusion criteria for 
participation were the same as in previous reports, and one control subject who did not 
provide a urine sample was removed.  Exposed and control subjects were frequency matched 
by gender.  As shown in Table 2.1, demographic characteristics were similar among exposed 
and control workers in terms of gender, age and smoking status. Smoking status was highly 
correlated with gender.  Personal protective equipment was not used. 
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Table 2.1. Demographic characteristics of the study population. 
Exposure Status Gender n (%) Age 
median (range) 
Current smokers 
n (%) 
Smoking intensitya 
median (range) 
Control Male 52 (37.4) 28 (18–51) 36 (69.2) 10 (1–40) 
  
Female 87 (62.5) 28 (18–51) 3 (3.45) NRb 
  
All 139 (100) 28 (18–51) 39 (28.1) 10 (1–40) 
Exposed Male 86 (34.4) 23 (18–44) 47 (54.7) 10 (1–30) 
  
Female 164 (65.6) 33 (18–52) 5 (3.05) 4.5 (2–10) 
  
All 250 (100) 29 (18–52) 52 (20.8) 7 (1–30) 
a
 Average number of cigarettes/day. 
b
 Not reported. 
 
Full-shift exposures to benzene were monitored with passive samplers (Organic Vapor 
Monitors, 3M Corp., St. Paul, MN), and urine was collected from each participant at the end 
of each working shift for which air had been monitored. Air samples were analyzed for 
benzene by gas chromatography with flame-ionization detection as described previously 
(Vermeulen et al., 2004).  The nominal LOD was 0.20 ppm of benzene in air.   
Urine samples were collected repeatedly (up to 4 times) in 139 subjects at intervals of 
about 42 days (median value) from June 2000 to June 2001. The other 250 subjects provided 
a single urine specimen.  Urine samples were aliquoted immediately after collection, and 
stored at -80oC for 1.6 – 4.0 y (for UBz) and 2.2 – 3.8 y (for urinary metabolites) prior to 
analysis.  Samples were identified by randomly assigned numbers. Information about 
exposure levels and demographic factors were released after all assays had been completed 
and results reported to collaborators.  A total of 620 urine specimens were analyzed from 389 
subjects.  Urinary creatinine was quantified with a commercial kit (Monarch Instrument, 
Amherst, NH) as described previously (Rothman et al., 1998).  
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For quality control purposes, positive controls were assayed with each batch of urine 
samples. They were prepared from a single urine specimen obtained from an unexposed 
volunteer to which had been added sufficient quantities of standard analytes to achieve the 
following concentrations: UBz – 24.5 nM, MA – 32.3 M, SPMA – 2.65 M, and PH – 92.8 
M, CA – 94.1 M and HQ – 69.7 M.  Batches of positive controls were aliquoted into 2-
ml vials and stored at -80oC prior to analysis.   
This study was approved by the Institutional Review Boards of the University of North 
Carolina, the University of California, Berkeley, the U.S. National Cancer Institute and the 
Chinese Academy of Preventive Medicine.  
2.3.3. Measurement of Urinary Benzene 
Levels of UBz were determined according to the method of Waidyanatha et al. 
(Waidyanatha et al., 2001), with minor modifications. Briefly, to 0.5 ml of urine in a 2-ml 
vial containing ca. 0.5 g of NaCl was added one µl of 59.4 M [2H6]benzene in methanol 
(internal standard).  The vial was immediately sealed with a PTFE/silicone septum and 
benzene was extracted from the headspace with a 30-m polydimethylsiloxane fiber 
(Supelco, PA) at 40oC for 15 min.  Samples were analyzed by gas chromatography-mass 
spectrometry (GC-MS) in electron ionization (EI) mode using a HP 5980 Series II gas 
chromatograph coupled to a HP 5971-A mass selective detector. Sample injections were 
performed with a Varian Model 8200 autosampler (Walnut Creek, CA) equipped with a 
carousel (Strumenti Scientific, Padova, Italy).  The injector, MS-transfer line and ion source 
temperatures were 200, 280, and 168oC, respectively.  A DB-1 fused silica capillary column 
(60 m, 0.25-mm i.d., 0.25-m film thickness) was used with He as the carrier gas at a flow 
rate of 1 ml/min. The GC oven was held at 45oC for 9 min, and was then increased at 10 
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oC/min to 100 oC.  Late eluting compounds were removed by rapidly raising the oven 
temperature to 250oC. The mass spectrometer was operated with an electron energy of 70 eV, 
and ions were monitored at m/z 78 and 84 for benzene and [2H6]benzene, respectively.  The 
retention times were 8.56 and 8.50 min for benzene and [2H6]benzene, respectively. 
Quantification was based on peak areas relative to the isotopically labeled internal standard. 
2.3.4. Measurement of Benzene Metabolites 
Levels of CA, HQ, MA, PH and SPMA were determined according to the method of 
Waidyanatha et al., with minor modifications (Waidyanatha et al., 2001).  Briefly, to 0.5 ml 
of urine in a 4-ml vial was added 10 l of a mixture (in methanol) of 1.73 mM [13C2]MA, 
0.205 mM [2H5]SPMA, 6.24 mM [13C6]PH, 2.19 mM [2H4]CA, and 2.15 mM [13C6]HQ 
(internal standards). After adding 50 l of concentrated HCl, the mixture was extracted with 
1.5 ml of ethyl acetate and the organic phase, containing MA, SPMA, and free PH, CA, and 
HQ, was transferred to another 4-ml vial. Then, a 10-l aliquot of a mixture containing the 
above quantities of internal standards of PH, CA, and HQ was added to the aqueous phase, 
which was heated at 100oC for one h to hydrolyze the conjugates.  After cooling to room 
temperature, the aqueous phase was extracted with an additional 1.5 ml of ethyl acetate.  The 
two organic extracts were combined, dried with anhydrous Na2SO4, reduced under N2, 
transferred to a 500-l flat-bottomed insert, and brought to dryness under N2.  The residue 
was dissolved in 100 l hexane and derivatized with 100 l Tri-Sil reagent at 70oC for one h.  
Samples were analyzed by GC-MS in EI mode with the same instrumentation described 
above using automated liquid injection.  A 2-l injection was analyzed in splitless mode for 
SPMA; here, the GC oven was maintained at 75oC for 4 min, and was then increased at 
8oC/min to 245oC, where it was held for 10 min.  A 1-l portion was analyzed in (1:20) split 
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mode for PH, CA, HQ, and MA; here, the GC oven was maintained at 75 oC for 4 min, and 
was then increased at 10 oC/min to 230oC and held for 4 min.  In both cases, late eluting 
compounds were removed by rapidly raising the oven temperature to 270oC and holding this 
temperature for 15 min.  The following ions were monitored for trimethylsilyl (TMS)-
derivatives of the analytes: TMS-PH [m/z 166, M+], TMS-[13C6]PH [m/z 172, M+], TMS-CA 
[m/z 254, M+], [2H4]CA [m/z 258, M+], TMS-HQ [m/z 254, M+], TMS-[13C6]HQ [m/z 260, 
M+], TMS-MA [m/z 271, (M-15)+], TMS-[13C2]MA  [m/z 273, (M-15)+], TMS-SPMA [m/z 
252, (M-NH2COCH3)+], and TMS-[2H5]SPMA [m/z 257, M-NH2COCH3)+]. The respective 
retention times were 12.66, 12.66, 17.65, 17.62, 18.83, 18.83, 21.91, and 21.91 min for TMS-
PH, TMS-[13C6]PH, TMS-CA, TMS-[2H4]CA, TMS-HQ, TMS-[13C6]HQ, TMS-MA, and 
TMS-[13C2]MA in split mode, and 32.65 and 32.59 for TMS-SPMA and TMS-[2H5]SPMA in 
splitless mode.  Quantification was based on peak areas relative to the corresponding 
isotopically labeled internal standards.  
2.3.5. Creatinine Adjustment for Benzene Metabolites 
It is customary to adjust urinary metabolite levels for urinary creatinine to control for 
urine volume at the time of collection.  However, such adjustments can introduce biases and 
reduce precision, due to variation of creatinine levels with gender, age, body mass index, and 
other physiological factors (Zacur et al., 1997; Hall Moran et al., 2001; Ikeda et al., 2003).  
In preliminary regression models, we observed lower adjusted-R2 values using creatinine-
adjusted metabolite levels compared to unadjusted values.  We also found significant effects 
of age, gender and body mass index upon creatinine levels in our samples of workers. Thus, 
for all statistical analyses we used metabolite levels without adjustment for urinary 
creatinine. The following median levels of urinary creatinine were observed in our samples 
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of workers: all subjects – 11.6 mM; female controls – 10.4 mM; male controls – 11.5 mM; 
female exposed – 11.4 mM; and male exposed – 13.9 mM. 
2.3.6. Predicting Low-level Exposures from Urinary Benzene 
All air samples from control subjects were below the LOD (n = 160) and some 
measurements from exposed subjects were either below the LOD (n = 70) or were missing (n 
= 23).  In order to predict the levels of benzene exposure in these samples, we used the log-
scale linear regression of UBz on air benzene (228 data pairs) shown in Figure 2.2.A.  For 
subjects having multiple air and urine samples, the mean values of the natural logarithms of 
urine and air levels were used.  The following calibration curve was derived from the 
parameters of the simple linear regression: ln(UBz, nmol/l) - 5.42benzene (ppm) = exp
0.886
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Note that these predicted values of benzene exposure include contributions from smoking.  
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Figure 2.2. Calibration curve for predicting air concentrations of benzene from the 
corresponding urinary levels.  (A) Points represent observed air and urine concentrations 
and the line represents the least-squares regression equation: ln(urinary benzene, nM) = 5.42 
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+ 0.886×ln(air benzene, ppm) (n = 228, adjusted R2 = 0.428; 95 confidence of intercept, 5.24 
– 5.61; 95 confidence interval of slope, 0.752 - 1.02). The curves represent 95% confidence 
intervals and 95% prediction intervals. (B) Scatter plot of urinary benzene versus air benzene 
from the current study (open circles) and data from Ghittori et al. (Ghittori et al., 1993) 
obtained from measurements from 63 nonsmoking subjects exposed to benzene (closed 
circles). 
2.3.7. Investigating Exposure-Metabolite Relationships 
The relationships between levels of metabolites and exposure were explored using 
median values and interquartile ranges.  Based upon 13 groups of 30 subjects stratified by 
exposure the following median air concentrations (ppm) were observed: 0.001, 0.002, 0.004, 
0.007, 0.027, 0.273, 0.508, 0.689, 1.02, 1.57, 2.41, 5.45, and 15.4.  Multiple comparison tests 
were utilized to generate step-functions showing statistically significant increases in 
geometric mean (GM) metabolite levels from group to group.  These step functions were 
used to define levels of benzene exposure at which metabolite concentrations were 
statistically distinguishable from background values.   
A similar grouping scheme (30 subjects stratified by exposure level) was used to 
investigate the dose-related production of each benzene metabolite, after adjustment for 
background metabolite levels.  Background levels were estimated as median metabolite 
concentrations in 60 subjects with the lowest benzene exposures (median predicted benzene 
concentration = 0.002 ppm).  Adjustment involved subtracting background metabolite levels 
from the corresponding urine concentrations observed in each subject.  After grouping by 
benzene exposure (n = 30 per group) the median metabolite level in each group was divided 
by the median air concentration of benzene to estimate dose-related production of each 
metabolite (M per ppm benzene) for the 9 groups with estimated median benzene exposures 
between 0.027 and 15.4 ppm.  Uncertainties in estimated median values of benzene exposure 
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and background-adjusted metabolite levels were evaluated via a bootstrapping technique as 
described below. 
2.3.8. Statistical Analyses 
All statistical analyses were performed using SAS software for Windows v. 9.12 (SAS 
Institute, Cary, NC).  Between one and four concurrent air and urine samples from each 
subject were available for statistical analysis (median = 2/subject).  For subjects with 
multiple samples, estimated individual GM levels were used for all analyses.  Non-detectable 
levels of urinary analytes were replaced by LOD/ 2  [UBz: n = 8 (1.29%); SPMA: n = 30 
(4.84%)] (Hornung and Reed, 1990).  The precision of the assay for each urinary analyte was 
estimated as the coefficient of variation (CV) from 84 pairs of duplicate urine samples (from 
exposed and control workers), which had been aliquoted and assigned random identification 
numbers prior to shipment to the laboratory.  The CV was estimated as 2exp( ) -1CV sε= , 
where 2sε  is the estimated error variance obtained from a one-way analysis of variance of the 
log-transformed levels of each analyte (Proc NESTED of SAS).   
To evaluate possible effects of sample storage at -80oC upon the levels of UBz and the 
benzene metabolites, the logged level of each urinary analyte was regressed upon the 
corresponding logged air concentration of benzene and the time of storage using a mixed-
effects model, which included a random-subject effect to account for multiple urine 
specimens being collected from some persons (Proc MIXED of SAS). 
Median levels of benzene exposure and those of the urinary metabolites were compared 
by exposure status, gender, and smoking status using the Wilcoxon two-sample test (two-
sided tests with a significance level of 0.05, Proc NPAR1WAY of SAS).  Trends of (median) 
metabolite levels versus benzene exposure were tested with Spearman correlation 
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coefficients, (Proc CORR of SAS).  Differences in mean values of logged metabolite levels 
among groups of 30 subjects aggregated by benzene exposure were tested using Tukey's 
multiple comparisons test (Proc GLM of SAS).  These tests were used to determine levels of 
benzene exposure where metabolite levels could be differentiated from background values. 
We predicted air exposures of control subjects from their levels of urinary benzene and 
used these predicted exposures to group subjects for aggregated analyses.  Thus, to estimate 
dose-related profiles of metabolite production, and the associated uncertainties, bootstrapping 
was performed based upon median values of background-adjusted metabolite levels and the 
corresponding levels of benzene exposure.  First, resampling was conducted (with 
replacement) 1000 times to predict nondetected air exposures from urinary benzene levels, 
using the 228 data pairs shown in Figure 2.2.  For each of the 1000 samples, predicted air 
concentrations were combined with observed air concentrations, median background levels 
from the lowest 60 exposed persons were subtracted from individual metabolite levels, and 
data were aggregated for groups of 30 subjects.  Then, 5th, 50th and 95th percentiles of the 
distributions of estimated median values of air and metabolite concentrations were obtained.  
Differences in dose-related production of each metabolite between adjacent exposure groups 
were evaluated with Kruskal-Wallis tests for overall group effects and trends (Proc FREQ of 
SAS).   
2.4. Results 
2.4.1. Precision, Sensitivity and Storage Stability 
Estimates of CVs for the urinary analytes were as follows: UBz – 21.1%, MA – 6.15%, 
SPMA – 46.2%, PH – 4.97%, CA – 6.50%, and HQ – 4.81%.  Based on a volume of 0.5 ml 
urine and a signal-to-noise ratio of 3:1, the following LODs were estimated: UBz, 0.128 nM, 
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MA, 5.66 nM (one µl injected with 1:20 split), and SPMA, 0.836 nM (2 l with splitless 
injection).  Values of LOD were not estimated for PH, CA, and HQ due to the presence of 
background levels of these compounds in all urine specimens. The LOD for measurements of 
airborne benzene had previously been assigned a nominal value of 0.2 ppm (Vermeulen et 
al., 2004).  When the period of storage was included as a fixed effect in mixed-effects 
models of the logged levels of UBz and the benzene metabolites on the logged benzene air 
concentrations, the observed regression coefficients were very small relative to the intercepts 
and showed no evidence of statistical significance (p > 0.2).  This indicates that all analytes 
were stable during long periods of storage at -80oC in this study. 
2.4.2. Summary Statistics 
Estimates of median levels, ranges and interquartile ranges of air exposures to benzene 
and all urinary analytes are summarized in Table 2.2, after stratification by exposure status, 
gender, and smoking status.  Among occupationally exposed subjects, air levels of benzene 
ranged from 0.017 to 88.9 ppm (interquartile range: 0.529 – 3.34 ppm), with median values 
of about 1.2 ppm in all categories of subjects.  Among control subjects, median exposures 
(predicted from UBz levels) were between 3 and 6 parts per billion (ppb) depending upon 
gender and smoking status.  Although air and urinary concentrations of benzene were 
comparable in all categories of exposed workers, females had significantly higher median 
levels of SPMA (p = 0.048) and PH (p = 0.038) than males.  No significant differences were 
observed between smokers and nonsmokers in the exposed group.  Control subjects who 
were smokers had higher median levels of all urinary analytes than nonsmokers, notably UBz 
(p = 0.003), CA (p = 0.034) and HQ (p = 0.001), indicating the likely presence of these 
analytes in cigarette smoke.  Although there were no significant effects of gender on 
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metabolite levels in control subjects, when nonsmokers were further stratified by gender, 
females (n = 84) had significantly higher median levels of PH (63.3 vs. 46.4 M, p = 0.037) 
and CA (13.2 vs. 7.99 M, p = 0.010) than males (n = 16).   
Table 2.2. Summary statistics for exposure to benzene and urinary analytes. 
 Control§  Exposed§§ 
Variable Female Male Nonsmoker Smoker  Female Male Nonsmoker Smoker 
  
(n = 87) (n = 52) (n = 100) (n = 39)  (n = 164) (n = 86) (n = 198) (n = 52) 
Air benzene†          
Median 3.4 3.71 3.09 6.07  1.28 1.05 1.18 1.18 
Range 0.146-21.2  0.146-533  0.146 -21.2  0.146 -533   0.017-88.9  0.122-50.2  0.017-88.9  0.122-40.1  
IQ range 1.70-6.80  2.13-9.71  1.70 -5.91  2.56 -17.6   0.523-4.21  0.572-2.36  0.520-3.34  0.588-3.02  
p-value 0.273 0.003  0.588 0.889 
UBz (nM)                  
Median 1.48 1.59 1.36 2.47  283 216 267 197 
Range 0.091-7.47 0.091-130 0.091-7.47 0.091-130  6.21-53900 19.4-42600 6.21-53900 19.4-41600 
IQ range 0.799-2.73 0.973-3.74 0.797-2.41 1.15-6.32  87.3-1020 96.3-643 96.3 -810 85.3-654 
p-value 0.273 0.003  0.635 0.702 
MA (M)          
Median 1.06 1.09 1.06 1.11  13.5 10.3 12.3 12.4 
Range 0.152-6.17 0.132-5.78 0.152-6.17 0.132-4.96  0.644-426 1.50-370 0.644-426 2.15-347 
IQ range 0.549-1.75 0.774-1.72 0.543-1.70 0.803-1.74  6.33-34.5 5.39-22.4 6.13-28.5 6.22-28.4 
p-value 0.565 0.384  0.272 0.473 
SPMA (nM)                  
Median 1.94 3.24 1.96 3.17  262 137 228 171 
Range 0.591-86.4 0.591-68.1 0.591-86.4 0.591-68.1  1.50-29400 3.68-33000 1.50-29400 4.06-33000 
IQ range 1.17-3.62 1.04-6.93 1.13-4.25 1.09-7.37  50.6-788 48.9-353 50.1-631 47.9 -412 
p-value 0.479 0.493  0.048 0.638 
PH (M)          
Median 61.4 53.2 61.3 56.3  171 134 158 135 
Range 9.48-208 7.58-336 9.48-208 7.58-336  15.9-3740 41.8-4140 15.9-4140 41.8-3380 
IQ range 45.0-103 28.8-82.0 43.7-89.6 29.0-98.5  102-310 86.6-190 100-261 84.6-313 
p-value 0.117 0.415  0.038 0.391 
CA (M)                  
Median 13.3 12.7 12.1 15.7  21.8 21 20.5 23.7 
Range 2.30-61.1 2.45-46.6 2.30-61.1 2.45-46.6  3.50-420 4.20-438 3.50-438 7.08-348 
IQ range 8.06-17.0 7.07-18.9 7.50-15.8 9.90-19.8  13.3-33.0 12.6-29.4 12.6-32.1 13.8-35.5 
p-value 0.786 0.034  0.411 0.153 
HQ (M)                  
Median 5.95 7.35 5.93 8.52  17.7 18.5 17.1 19.6 
Range 1.54-39.1 1.32-41.7 1.40-39.1 1.32-41.7  2.29-427 3.20-341 2.29-427 5.76-375 
IQ range 4.44-8.88 4.48-11.7 4.11-8.86 5.65-13.9  11.2-36.8 11.5-27.8 10.4-29.1 14.9-35.9 
p-value 0.106 0.001   0.925 0.084 
Legend: IQ range - interquartile range, benzene - benzene in air, UBz - urinary benzene, MA - E,E- muconic 
acid, SPMA - S-phenylmercapturic acid, PH - phenol, CA - catechol, HQ - hydroquinone. † Exposure to 
benzene for control subjects was predicted from the relationship between UBz and air exposure. § unit of air 
benzene, ppb.  §§ unit of air benzene, ppm. 
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Figure 2.3. Levels of urinary metabolites versus air exposures to benzene.  Each vertical 
box depicts median, 25th and 75th percentiles of a given metabolite at the median level of 
exposure for data grouped by exposure levels (30 subjects per group). Horizontal lines 
represent groups with equivalent metabolite levels (Tukey’s multiple comparison tests).  
Arrows represent air exposure levels where it is possible to distinguish benzene metabolites 
from background sources.  Legend: MA - E,E-muconic acid, SPMA - S-phenylmercapturic 
acid, PH – phenol, CA - catechol, and HQ– hydroquinone. 
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2.4.3. Distinguishing Benzene Metabolites from Background Sources 
Figure 2.3 shows median levels and interquartile ranges for concentrations of each 
metabolite among groups of 30 subjects aggregated by benzene exposure.  As exposure 
increased, the levels of metabolites also increased (estimated Spearman coefficients of 
median values for PH: 0.973, HQ: 0.945, CA: 0.934, MA: 0.973, and SPMA: 0.973, all with 
p < 0.001).  The step functions signify nominal exposure concentrations at which statistically 
significant increases in metabolite levels were observed.  As exposure increased, the 
contribution of benzene to each metabolite could consistently be discerned at some point 
(Tukey’s multiple comparisons test), as indicated by an arrow in Figure 2.3.  Although there 
were marginal increases in median levels of MA, PH, CA, and HQ at median benzene 
exposures as low as 0.02 ppm, elevations were not unambiguous below air concentrations of 
0.2 ppm for MA and SPMA, 0.5 ppm for PH and HQ and 2 ppm for CA.  From these results, 
it appears that none of the metabolites would be useful for biomonitoring of benzene at 
environmental levels (generally below 0.01 ppm). 
2.4.4. Dose-Related Production of Benzene Metabolites 
Median urine concentrations of all metabolites per ppm of benzene exposure are 
presented in Figure 2.4 for the 9 groups of workers having exposures above 0.01 ppm (after 
adjustment for background values).  Each point in the figure and the corresponding error bars 
represent median values and 5th and 95th percentiles of distributions of median values, as 
determined by bootstrapping.  These curves point to the dose-related production of benzene 
metabolites according to the pathways shown in Figure 2.1.  Over the range of exposures 
investigated (median benzene concentrations between 0.027 and 15.4 ppm) significant 
downward trends in metabolite production were observed (p < 0.001, Kruskal-Wallis tests)  
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Figure 2.4. Dose-related production of urinary metabolites versus air exposure to 
benzene. Each point and the corresponding error bars represent median values and 5th and 
95th percentiles of distributions of estimated median values of air benzene and dose-related 
metabolite levels (background-adjusted metabolite concentration/air benzene concentration) 
for groups of 30 subjects, determined by bootstrapping (1000 iterations).  Legend: MA - E,E-
muconic acid, SPMA - S-phenylmercapturic acid, PH – phenol, CA - catechol, and HQ– 
hydroquinone Total – total metabolites. 
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for all major metabolites (PH, CA, HQ and MA) and for total metabolites (p < 0.001), while 
a significant upward trend was observed for SPMA (p < 0.001).  The downward trend of total 
benzene metabolites is consistent with partial saturation of CYP metabolism of benzene 
between 0.027 and 15.4 ppm.  The transitions were particularly apparent between the first 
and second exposure groups (median benzene concentrations between 0.027 and 0.274 ppm 
for all metabolites.   
 
2.5. Discussion 
The connections between benzene metabolism and toxicity have been extensively 
debated (Smith, 1996; Golding and Watson, 1999; Snyder, 2000b; Lovern et al., 2001; 
Snyder, 2004).  To gain a better understanding of human benzene metabolism, we measured 
the key metabolites (PH, CA, HQ, MA and SPMA) and UBz in 250 benzene exposed 
workers and 139 control workers from a Chinese population.  Of the studies devoted to 
urinary biomarkers of benzene in Asian populations, none compared levels of all key 
metabolites with air levels representing both environmental and occupational exposures (Ong 
et al., 1995; Ong et al., 1996; Rothman et al., 1998; Qu et al., 2000; Melikian et al., 2002; 
Waidyanatha et al., 2004).  Our goals were to determine the usefulness of the urinary 
metabolites as biomarkers of benzene exposure in exposed and control subjects and to 
elucidate the dose-related patterns of benzene metabolism along the prominent pathways 
shown in Figure 2.1.   
Since control workers in our study were exposed to benzene in environmental air and 
tobacco smoke, we predicted their exposures from the corresponding UBz concentrations, 
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using a calibration curve obtained from exposed subjects (Figure 2.2).  Such predictions 
should be reasonably unbiased, given previous findings of strong linear trends between levels 
of benzene in urine and environmental air (Ghittori et al., 1993; Ghittori et al., 1995; 
Fustinoni et al., 1999; Fustinoni et al., 2005a; Fustinoni et al., 2005b).  This conjecture is 
reinforced by Figure 2.2B which plots levels of UBz versus air benzene from the current 
study (open circles) as well as those reported by Ghittori et al. (Ghittori et al., 1993) for 63 
nonsmoking workers exposed to measured benzene concentrations between 0.01 and 4 ppm 
(closed circles).  The two sets of measurements point to a linear log-scale relationship down 
to the lowest measured air level of about 0.01 ppm.  Also, the median benzene air 
concentration predicted from UBz levels for our control subjects (3.55 ppb, n = 139) is 
similar to air concentrations estimated from personal monitoring of adult populations in the 
U.K. (3.82 ppb daytime mean value, n = 50) (Leung and Harrison, 1998), in Germany (3.44 
ppb median value, n = 113) (Hoffmann et al., 2000), in the U.S. (2.29 – 7.01 ppb range of 
median values for 5 cities, n = 421) (Rappaport and Kupper, 2004), and Italy (2.82 and 1.88 
ppb for control subjects in two cities, n = 107) (Fustinoni et al., 2005b).   
Comparing levels of urinary analytes between smoking and nonsmoking controls, the 
median values of UBz, CA, HQ, MA and SPMA were all higher in smokers, while the 
median level of PH was marginally lower in smokers (Table 2.1).  The apparent anomaly for 
PH is probably related to gender because male controls had lower PH levels than females and 
92% of the smokers were male.  [Among male controls, smokers had a higher median level 
of PH (58.7 M, n = 36) than male nonsmokers (46.4 M, n = 16)].  Other investigators have 
reported that non-occupationally exposed smokers had significantly higher urinary levels of 
UBz (Ghittori et al., 1993; Ghittori et al., 1995; Fustinoni et al., 1999; Fustinoni et al., 
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2005a), MA (Melikian et al., 1994; Ghittori et al., 1995; Scherer et al., 1998; Melikian et al., 
1999; Taniguchi et al., 1999; Waidyanatha et al., 2004), and SPMA (Ghittori et al., 1995; 
Maestri et al., 1997; Waidyanatha et al., 2004) than nonsmokers.   
To estimate the equivalent air level of benzene from cigarette consumption, we 
regressed the (logged) predicted air concentration of benzene on the number of cigarettes 
smoked per day among control subjects.  This led to the following relationship:  
ln(benzene, ppm) = -5.81 + 0.050(cigarettes/d) (n = 134, p-value for slope = 0.003),  
from which we predict that smoking 20 cigarettes/d would be equivalent to an 
occupational benzene exposure of 8.2 ppb (26 g/m3).  This estimated benzene exposure of 
8.2 ppb is the same as that predicted from British data (Duarte-Davidson et al., 2001) for an 
urban smoker consuming 20 cigarettes/d.   
 In order to distinguish benzene-derived metabolites from background levels of the 
same compounds, we investigated median metabolite levels for groups of 30 subjects, 
aggregated by benzene exposure (Figure 2.3).  Using statistical significance to discern 
exposure-related increases in urinary levels, we detected marginal elevations at benzene 
exposures between 0.02 and 0.1 ppm for all metabolites except SPMA.  However, when we 
considered exposure levels which produced unambiguous increases in metabolite 
concentrations, MA and SPMA were the most sensitive biomarkers of exposure to benzene 
(about 0.2 ppm), followed by PH and HQ (about 0.5 ppm) and CA (about 2 ppm).   
Using aggregated data, we also observed changes in dose-related metabolism of benzene 
(Figure 2.4) for median benzene exposures between 0.027 and 15.4 ppm.  We anticipated that 
saturable metabolism would be detected in this range, given results from other Chinese 
studies (Rothman et al., 1998; Waidyanatha et al., 2001; Melikian et al., 2002; Waidyanatha 
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et al., 2004), and because benzene, oxepin and PH are all thought to compete for the same 
enzymes (CYP2E1) (Gilmour et al., 1986; Snyder et al., 1993; ATSDR, 1997).  And, in fact, 
downward trends were apparent for dose-related production of PH (9.9-fold), CA (26-fold), 
HQ (3.4-fold), MA (2.5-fold), and total metabolites (14-fold) (Figure 2.4).  The 2.5-fold 
decrease observed for MA is comparable to a 3.3-fold reduction that we estimated from 
grouped data reported by Melikian et al. (Melikian et al., 2002) (using differences between 
post-work and pre-work measurements of MA) for Chinese workers exposed to benzene 
concentrations between 0.34 and 22.6 ppm (estimated mean values).   
Surprisingly, SPMA displayed an upward trend of production, with a 5.8-fold increase 
between 0.027 and 15.4 ppm (Figure 2.4).  This might reflect the action of glutathione-S-
transferase or be the result of mechanisms (Henderson et al., 2005a) or sites of formation of 
SPMA which differ fundamentally from those of the other metabolites.   
 It is noteworthy that the most dramatic reductions in dose-related metabolism 
occurred between the first two groups in Figure 2.4, with benzene exposures of 0.027 and 
0.274 ppm, respectively.  In this range, production of CA dropped by 16-fold and that of PH 
by 4.4-fold.  Yet, only marginal reductions were observed in this exposure range for 
production of MA (44% reduction) and HQ (36% reduction).  Thus, it appears that 
metabolism shifted away from CA and PH at low doses in favor of MA and HQ, the only 
major benzene metabolites requiring two CYP oxidations (Figure 2.1).  When exposures 
exceeded about one ppm, the curves in Figure 2.4, representing major metabolites (PH, MA, 
HQ, and CA), became quasi-parallel, suggesting that metabolism of benzene to BO had 
become rate-limiting.   
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If our conjecture is correct that exposures to benzene below one ppm favor production 
of HQ and MA, there could be important implications for risk assessment.  Certainly, HQ is 
the precursor of 1,4-benzoquinone, which is generally regarded as most hematotoxic of the 
benzene metabolites (Smith, 1996; Snyder and Hedli, 1996; Smith et al., 2004; Snyder, 2004; 
Inayat-Hussain and Ross, 2005), and MA is derived from the extremely reactive and toxic 
muconaldehydes (Witz et al., 1990; Witz et al., 1996; Golding and Watson, 1999; Amin and 
Witz, 2001; Oshiro et al., 2001).  We are currently applying various nonlinear models to 
these data to more fully examine the dose-related metabolism of benzene and to estimate 
effects of physiological and genetic factors upon benzene metabolites.   
 
  
CHAPTER 3.   
MODELING HUMAN METABOLISM OF BENZENE 
FOLLOWING OCCUPATIONAL AND 
ENVIRONMENTAL EXPOSURES 
[Kim S, Vermeulen R, Waidyanatha S, Johnson AB, Lan Q, Rothman N, et 
al. Cancer Epidemiol Biomarkers Prev 2006, in press.] 
 
3.1. Abstract 
We used natural spline (NS) models to investigate nonlinear relationships between 
levels of benzene metabolites [E,E-muconic acid (MA), S-phenylmercapturic acid (SPMA), 
phenol (PH), hydroquinone (HQ), and catechol (CA)] and benzene exposure among 386 
exposed and control workers in Tianjin, China.  After adjusting for background levels 
(estimated from the 60 control subjects with the lowest benzene exposures), expected mean 
trends of all metabolite levels increased with benzene air concentrations over 0.03 – 88.9 
ppm.  Molar fractions for PH, HQ and MA changed continuously with increasing air 
concentrations, suggesting that competing CYP-mediated metabolic pathways favored MA 
and HQ below 20 ppm and favored PH above 20 ppm.  Mean trends of dose-specific levels 
(M/ppm benzene) of MA, PH, HQ, and CA all decreased with increasing benzene exposure, 
with an overall 9-fold reduction of total metabolites.  Surprisingly, about 90% of the 
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reductions in dose-specific levels occurred below about 3 ppm for each major metabolite.  
Using general linear models (GLM) with NS-smoothing functions we detected significant 
effects upon metabolite levels of gender, age and smoking status.  Metabolite levels were 
about 20% higher in females and decreased between one and two percent per year of life.  
Also, levels of HQ and CA were greater in smoking subjects.  Overall, our results indicate 
that benzene metabolism is highly nonlinear with increasing benzene exposure above 0.03 
ppm and that current human toxicokinetic models do not accurately predict benzene 
metabolism below 3 ppm.  Our results also suggest that GLM+NS models are ideal for 
evaluating nonlinear relationships between environmental exposures and levels of human 
biomarkers. 
 
3.2. Introduction 
Benzene is an important industrial chemical that is also ubiquitous in the environment 
due to emissions from gasoline and combustion of hydrocarbons and tobacco (Wallace, 
1996; ATSDR, 1997).  Occupational exposure to benzene can cause blood disorders, 
including aplastic anemia, myelodisplastic syndrome, and acute myelogenous leukemia 
(Hayes et al., 1997; Savitz and Andrews, 1997).  Significant decreases in the numbers of 
white blood cells and platelets have recently been reported in workers exposed to less than 
one ppm of benzene (Lan et al., 2004).  These toxic effects are thought to arise from 
metabolism of benzene, which proceeds along several lines, as illustrated in Figure 3.1.  Of 
the various metabolites, 1,4-benzoquinone and the muconaldehydes are regarded as the most 
toxic species.  However, the mechanism by which benzene causes toxicity and the shape of 
the exposure-response relationship are not well understood (Ross, 2000; Snyder, 2004).  
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We recently reported dose-specific urine concentrations of the major urinary metabolites 
of benzene, namely, phenol (PH), catechol (CA), hydroquinone (HQ), and E,E-muconic acid 
(MA), and a minor metabolite, S-phenylmercapturic acid (SPMA), in 250 benzene-exposed 
and 139 control workers from Tianjin, China (Kim et al., 2006b).  After grouping subjects 
according to their benzene exposures (30 subjects per group), median metabolite levels 
increased non-linearly with increasing median benzene concentrations between 0.03 and 20 
ppm while median dose-specific levels of total metabolites (µM/ppm benzene) decreased 
about 10 fold.   
We sought a parsimonious statistical model with which to elaborate on our previous 
grouped analyses (Kim et al., 2006b) and to determine effects of significant covariates, such 
as gender, age and smoking status, on the levels of benzene metabolites.  Given the nonlinear 
relationships involved, we selected natural splines (NS) as basis functions for these models 
because they use standard (least-squares or maximum-likelihood) methods for estimating 
parameters and for conducting formal tests; they can be used to represent predictors in final 
models; and they can easily be added to generalized linear models (GLM) for considering 
covariate effects (Durrleman and Simon, 1989; Heuer, 1997; Harrell, 2001; Samoli et al., 
2005).  Although generalized linear models with natural splines (GLM+NS) have been used 
in time-series studies of health effects associated with community air pollution (Dominici et 
al., 2002), we could find no reports of their applications to characterize exposure-biomarker 
relationships.   
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Figure 3.1.  Simplified metabolic scheme for benzene showing major pathways. 
 
3.3. Materials and Methods 
3.3.1. Subject Recruitment and Sample Collection 
Exposed and control subjects, from two shoe-making factories and three clothes-
manufacturing factories, respectively, in Tianjin, China, were recruited with informed 
consent as described previously (Lan et al., 2004; Vermeulen et al., 2004; Kim et al., 2006b).  
After excluding three control subjects, who had missing values of at least one metabolite, the 
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samples included 250 exposed subjects and 136 control subjects.  Exposed and control 
subjects were frequency matched by region and gender. Table 3.1 shows summary statistics 
for the gender, age and smoking status of participants.  Demographic data were obtained by 
questionnaires at the time of recruitment. 
Table 3.1.   Demographic characteristics of the study population. 
Air Benzene Age Current 
smokers 
Smoking 
intensitya Exposure 
Status Gender n (%) 
Median (range) Median (range) n (%) 
Median 
(range) 
Control Male 52 (38.2) 3.71 (0.146 – 533) ppb 28 (18–51) 36 (69.2) 10 (1–40) 
 Female 84 (61.8) 3.39 (0.146 – 21.2) ppb 28 (18–51) 3 (3.57) NRb 
  All 136 (100) 3.48 (0.146 – 533) ppb 28 (18–51) 39 (28.71) 10 (1–40) 
Exposed Male 86 (34.4) 1.05 (0.122 – 50.2) ppm 23 (18–44) 47 (54.7) 10 (1–30) 
 Female 164 (65.6) 1.28 (0.017 – 88.9) ppm 33 (18–52) 5 (3.05) 4.5 (2–10) 
  All 250 (100) 1.18 (0.017 – 88.9) ppm 29 (18–52) 52 (20.8) 7 (1–30) 
a
 Average number of cigarettes/day. 
b
 Not reported. 
 
Methods of sampling air and urine were also previously described (Lan et al., 2004; 
Vermeulen et al., 2004; Kim et al., 2006b).  Briefly, personal full-shift air measurements 
were matched with post-shift urine samples from exposed and control workers.  Of the 386 
subjects in this analysis, 139 had repeated measurements of air and urine, making a total of 
617 matched air/urine samples.  Among subjects with repeated measurements, the median 
number of paired air and urine samples was three (range: 2 – 4). 
This study was approved by the Institutional Review Boards of the University of North 
Carolina, the University of California, Berkeley, the U.S. National Cancer Institute and the 
Chinese Academy of Preventive Medicine. 
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3.3.2. Measurements of Air and Urinary Analytes 
The methods of measuring analytes in air and urine were described previously 
(Vermeulen et al., 2004; Kim et al., 2006b).  Briefly, benzene and toluene were measured in 
air using passive personal monitors (Organic Vapor Monitors, 3M, St. Paul, MN) followed 
by solvent desorption and gas chromatography (Vermeulen et al., 2004).  Urinary benzene 
was determined by gas chromatography-mass spectrometry (GC-MS) using head-space solid-
phase microextraction according to Waidyanatha et al. (Waidyanatha et al., 2001).  Urinary 
PH, CA, HQ, MA and SPMA were measured as trimethylsilylether derivatives by GC-MS 
according to Waidyanatha et al. (Waidyanatha et al., 2004).  Quantification of all urinary 
analytes was based on peak areas relative to the corresponding isotopically labeled internal 
standards.   
All air samples from control subjects were below the nominal limits of detection (LOD) 
of 0.2 ppm for benzene and 0.3 ppm for toluene.  In addition, some air measurements from 
exposed subjects were below the LOD (n = 70 for benzene and 67 for toluene) or were 
missing (n = 23).  Air concentrations for these samples were predicted from the simple linear 
regression of levels of urinary benzene or toluene on the corresponding air levels (in log 
scale) as described previously for benzene(Kim et al., 2006b).  The minor metabolite, SPMA, 
was not detected in 30 urine specimens; a value of LOD/ 2  = 0.591 nM was imputed to 
these samples (Hornung and Reed, 1990). 
3.3.3. Statistical Analysis 
For subjects with multiple measurements of air and urine, the estimated geometric mean 
air and urine concentrations were used in all statistical analyses.  Relationships between 
levels of the urinary metabolites and the corresponding air concentrations of benzene were 
 45 
examined using NS models with fixed knots.  Since metabolite levels from the 60 subjects 
with the lowest benzene exposures were used to estimate background levels of these 
metabolites (described later), NS models were applied to the remaining 326 subjects.  Each 
full NS model had the form,  
3
, ,0 ,1 ,2
1
E[ ln( ) | ln( )] ln( ) [ln( ) ]  m j j m m j m i j i
i
Y X X X
κ
β β β ξ +
=
= + + −    (1) 
where E[ln(Ym,j)|ln(Xj)] is the conditional mean value of ln(Ym,j) representing the natural-log 
transform of the level of the mth metabolite level in the jth subject at ln(Xj), the corresponding 
(logged) air concentration of benzene (ppm), and ξi is the location of the ith knot (in log-scale 
of benzene exposure) among total κ knots.   The function 3[ln( ) ]j iX ξ +−  equals 3[ln( ) ]j iX ξ−  
for positive values and equals zero otherwise.  Knots are joints of log-transformed air levels 
of benzene, showing different polynomial trends. They were assigned using equally spaced 
quantiles of the observations (Harrell, 2001).  After comparing NS models with 3 to 7 knots, 
based upon ‘corrected Akaike's Information Criteria’ (AICc) (Burnham et al., 2002), a 6-knot 
model was selected as a basis function for each metabolite.  Then a final model was assigned 
to each metabolite after removing insignificant knots by stepwise elimination (p = 0.10 for 
retention) (Marsh, 1986), while retaining the linear term representing benzene exposure, 
β1ln(Xj). 
Effects of covariates on metabolite levels were determined using GLM+NS models 
having the form:  
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3
, ,0 ,1 ,2 * * ,3
* 1 1
E[ ln( ) | ln( )] ln( ) [ln( ) ] + 
K
m j j m m j m i j i m k kj
i k
Y X X X C
κβ β β ξ β+
= =
= + + −      (2) 
where i* indicates the ith knot in final NS model for the mth metabolite (m = 1, …, 5, 
representing MA, SPMA, PH, CA and HQ, respectively), Ckj is the value of the kth covariate 
(k = 1, …, K) in the jth subject, and the remaining terms were the same as for Model (1).  The 
following covariates were evaluated: gender (0, female; 1, male), age (centered around the 
estimated mean value of 30.1 y, n = 326), smoking status (0, nonsmoker; 1, smoker), body 
mass index (BMI, centered around the estimated mean value of 22.5 kg/m2, n = 325), co-
exposure to toluene (0, low exposure relative to the median concentration of 3.29 ppm (n = 
326) ; 1, high exposure; antibiotics used within 30 days, (0, no; 1, yes), and current alcohol 
consumption status (0, no; 1, yes).  Main effects and two-way interactions were evaluated 
using Proc GLMSELECT of SAS, with backward selection based upon the smallest AICc 
values (Burnham et al., 2002), while retaining gender, age, BMI, and smoking status in all 
models.  With these main effects in the model, no other covariate effects or interactions were 
retained in final models.   
All statistical analyses were performed using SAS software for Windows v. 9.12 (SAS 
Institute, Cary, NC).   
3.3.4. Molar Fractions and Dose-specific Metabolism 
Let 
jm, j|X
ˆY be the conditional mean value of m, jY , representing the m
th
 metabolite level in 
the jth subject, given exposure level Xj under final Model (1).  The molar fraction of the mth 
metabolite, derived from benzene exposure of the jth subject, was estimated as 
, | ,
5
, | ,
1
ˆ( - )
ˆ( - )
j
j
m j X m b
m j X m b
m
Y Y
Y Y
=

, where m,bY  is the background level of the m
th
 metabolite and the 
 47 
denominator term represents ‘total’ metabolites from benzene.  We assigned values to m,bY  
using the median levels of Ym,j  observed in the 60 control subjects with the lowest benzene 
exposures (MA, 1.03 M; SPMA, 0.002 M; PH, 54.4 M; CA, 11.7 M; HQ, 6.43 M) 
(Kim et al., 2006b).  Dose-specific production (µM/ppm benzene) of the mth metabolite in 
the jth subject was estimated as ( )
jm, j|X m,b j
ˆY Y / X− , where Xj is that subject’s benzene 
exposure.  Negative values of ( )
jm, j|X m,b
ˆY Y−  in the above computations were replaced by 
zeros.  Because the proportions of negative values increased rapidly with decreasing 
exposure levels below 0.03 ppm, molar fractions and dose-specific metabolite levels were 
only evaluated for subjects exposed to benzene at or above 0.03 ppm (n = 267).  The 
following percentages of negative values were observed between 0.03 and 88.9 ppm: MA - 
0.29% and HQ - 14.6%.   
Uncertainties in the model predictions of dose-specific metabolite levels were evaluated 
via bootstrap resampling with 500 iterations (implemented with the SAS macro, %boot).  
The pool of all observed benzene exposures (each representing a different subject, n = 386) 
was sampled, with replacement, to select a reference group (the 60 lowest observations) and 
an exposed group (the 326 remaining observations).  Data from the exposed group (n = 326 
observations) were then used to construct NS models for the various metabolites, as 
described above for the original data set. 
 
3.4. Results 
3.4.1. Natural Spline Models 
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After removal of non-significant terms from Model (1), the following reduced models 
were selected for the 5 metabolites: 
MA: 3 3
, 1 3 +E[ln( ) | ln( )] = 1.11 + 0.188[ln( )] + 0.007[ln( )- ] - 0.022[ln( )- ]MA j j j j jY X X X Xξ ξ+ , 
SPMA: 3 3 3
, 1 2 + 5 +[ln( ) | ln( )] = -6.16 - 0.072[ln( )] + 0.040[ln( )- ] - 0.077[ln( )- ]  0.110[ln( )- ]E SPMA j j j j j jY X X X X Xξ ξ ξ+ +   
PH: 3
, 1E[ ln( ) | ln( )] = 4.21 + 0.009[ln( )] + 0.004[ln( )- ]PH j j j jY X X X ξ + , 
CA: 3
, 2E[ ln( ) | ln( )] = 2.64 + 0.034[ln( )] + 0.007[ln( )- ]CA j j j jY X X X ξ + , and 
HQ: 3 3
, 1 6 +ln( ) = 2.01 + 0.036[ln( )] + 0.004[ln( )- ] - 0.202[ln( )- ]HQ j j j jY X X Xξ ξ+ , 
where ξ1 = ln(0.004 ppm), ξ2 = ln(0.040 ppm), ξ3 = ln(0.513 ppm), ξ4 = ln(1.05 ppm), ξ5 = 
ln(2.37 ppm); ξ6 = ln(13.8 ppm).  These models are shown in Figures 3.2A-E along with the 
corresponding 95% confidence intervals and the individual observations for the 326 subjects. 
 
3.4.2. Effects of Covariates 
Effects of covariates, determined under Model (2) after adjustment for benzene 
exposure, are summarized in Table 3.2.  Age and/or gender were important explanatory 
variables for all 5 metabolites, with males and older subjects typically having lower 
metabolite levels.  Smokers had significantly higher levels of CA and HQ while lean subjects 
(lower BMI values) had significantly higher levels of CA.  Co-exposure to toluene was not 
significant in any of the models. Likewise, alcohol consumption was not a significant 
predictor of any benzene metabolite, either all subjects (n = 326 including 95 current 
drinkers) or in male subjects (n = 118 including 88 current drinkers). 
 49 
 


     



 









!





µµ µµ 







 


      



 









!







µµ µµ 


 





 


     



 









!





µµ µµ 





 


        



 









!





µµ µµ 




 


     



 









!





µµ µµ 





 


  






 









!





µµ µµ 



 









!







µµ µµ 



 









!





µµ µµ 



 









!





µµ µµ 



 









!





µµ µµ 
 
Figure 3.2. Basis functions of natural spline models fitting the 326 observations.  
Legends: MA, E,E-muconic acid; SPMA, S-phenylmercapturic acid; PH, phenol; CA, 
catechol; HQ, hydroquinone; open circle, observation; solid line, expected mean trends from 
the model; short dash, upper or lower bound of 95% confidence limit for expected means of 
dependant variable  
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Table 3.2.  Effects of significant covariates on metabolite levels (after adjustment for 
benzene exposure). 
Metabolite adj.R2 Covariate Parameter estimate p-value 
MA 0.814 Intercept 1.12 <.0001 
 
 Age -0.019 0.001 
 
 Sex (male) -0.273 0.013 
 
 BMI 0.012 0.332 
 
 Smoking 0.109 0.345 
SPMA 0.741 Intercept -6.19 <.0001 
 
 Age -0.015 0.136 
 
 Sex (male) -0.447 0.034 
 
 BMI -0.016 0.478 
  
  Smoking 0.203 0.360 
PH 0.605 Intercept 4.21 <.0001 
 
 Age -0.011 0.025 
 
 Sex (male) -0.209 0.032 
 
 BMI -0.003 0.773 
 
 Smoking 0.042 0.684 
CA 0.504 Intercept 2.65 <.0001 
 
 Age -0.002 0.716 
 
 Sex (male) -0.257 0.007 
 
 BMI -0.021 0.052 
  
  Smoking 0.329 0.001 
HQ 0.690 Intercept 1.95 <.0001 
 
 Age -0.011 0.015 
 
 Sex (male) -0.209 0.026 
 
 BMI 
-0.013 0.204 
  
  
Smoking 0.356 <0.001 
Legend: MA, E, E,-Muconic acid; SPMA, S-phenylmercapturic acid; PH, phenol; CA, catechol; HQ, hydroquinone; 
adj.R2, adjusted R2 of final model; 95% CI 95% confidence interval of parameter; age, centered around the mean 
value of 30.2 y; gender, (female, reference); BMI, body mass index, centered around the mean value of 22.5 kg/m2; 
smoking (nonsmoker, reference). 
 
3.4.3. Molar Fractions and Dose-specific Metabolism 
The background-adjusted urine concentration of mth benzene metabolite in the jth 
subject, i.e., ( )
jm, j|X m,b
ˆY Y− , increased monotonically with benzene exposure from 0.03 to 
88.9 ppm, as shown in Figure 3.3A.  The corresponding molar fractions, i.e.,    
are plotted versus benzene exposure in Figure 3.3B.   
, | ,
5
, | ,
1
ˆ( - )
ˆ( - )
j
j
m j X m b
m j X m b
m
Y Y
Y Y
=

 51 



    















"



!





 
#
$



%


%
&
"





 µµ µµ































"



!





 
#
$



%


%
&
"





 µµ µµ

 
         



    
'


!












"

(

(
)
*
+






'


!












"
 
Figure 3.3. Dose-dependent production of benzene metabolites.  Expected mean trends 
from natural spline models applied to subjects with benzene exposures between 0.03 and 
88.9 ppm (n = 267).  (A) Background-adjusted levels of benzene metabolites. (B) Molar 
fractions of benzene metabolites. 
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Molar fractions for MA and HQ increased 3-fold (4% to 12%) and 4-fold (3% to 11%), 
respectively, with benzene exposure from 0.03 to 20 ppm, and then decreased with benzene 
exposure above 20 ppm.  The molar fraction of PH showed the opposite behavior, with 
reduction from about 88% to 68%, for benzene exposures between 0.03 and 20 ppm, 
followed by increases above 20 ppm.  Molar fractions for CA and SPMA remained fairly 
constant, at about 6% and <1%, respectively, over the whole range of benzene levels, with 
some upwards curvature above 20 ppm.  
As shown in Figure 3.4, dose-specific metabolite levels [values of ( )
jm, j|X m,b j
ˆY Y / X− ], 
decreased with increasing benzene exposure for all but the minor product, SPMA.  At air 
concentrations above 20 ppm, shifts in dose-specific metabolism are apparent, with 
decreasing values for MA and HQ and increasing values for PH, CA and SPMA.  
Uncertainties in model predictions of dose-specific metabolite levels are indicated in Figure 
3.4 by iteration-trajectory plots, interquartile ranges, and 95% confidence intervals from the 
500 realizations of bootstrap resampling.  Although the 95% confidence intervals tended to 
be large for PH, HQ and CA at low benzene exposures (< 0.1 ppm), interquartile ranges were 
very modest for all metabolites over the entire range of predicted benzene exposures (0.03 – 
88.9 ppm).  Also, the median values from bootstrap analyses were very close to predictions 
from the NS models applied to the original 386 subjects in our study.    
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Figure 3.4. Dose-specific levels (µM/ppm) of benzene metabolites, predicted by natural 
spline models, for benzene exposures between 0.03 and 88.9 ppm.  Expected mean trends 
are indicated by red curves.  Yellow curves are the corresponding 50th percentiles of the 
sampling distributions of expected mean trends from 500 iterations of bootstrap resampling.  
The corresponding interquartile ranges (blue curves) and 95% confidence intervals (brown 
curves) of expected mean trends from bootstrap resampling are shown along with the 
individual iteration-trajectories (grey curves). 
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3.5. Discussion 
This study of 386 workers in Tianjin, China represents the most extensive set of 
measurements reported to date for paired air and urine samples from benzene-exposed 
workers and matched controls.  We previously published the empiric relationships between 
urinary metabolite levels and benzene exposure, based upon groups of these same subjects 
who had been aggregated by their exposure levels (Kim et al., 2006b).  Those preliminary 
analyses defined crude shapes of the exposure-biomarker relationships, which showed 
evidence of background levels of phenolic metabolites and MA (from dietary sources and 
smoking) and also of partial saturation of metabolic enzymes.  However, the preliminary 
analyses did not permit expected metabolite levels to be predicted at given air concentrations 
of benzene, nor did they allow effects of age, gender and other covariates to be estimated, 
after adjusting for benzene exposure.  In the current study, we found that GLM+NS models 
were ideal for characterizing the continuous relationships between metabolite levels and 
benzene exposures (Figure 3.2) and for testing effects of demographic factors (Table 3.2).  
Moreover, using GLM+NS models, we can avoid problems that have plagued generalized 
additive models that apply backfitting algorithms (Dominici et al., 2002; Ramsay et al., 
2003; He et al., 2006).   
Although various spline regression models have been applied to investigate covariates in 
time-to-health-effects or survival analyses (Durrleman and Simon, 1989; Hess, 1994; 
Herndon and Harrell, 1995; Heinzl and Kaider, 1997; Heuer, 1997; Little et al., 2000; 
Royston, 2000; Zhang et al., 2000; Dominici et al., 2002; Jemal et al., 2002; Binquet et al., 
2003; European Collaborative Study, 2003; HEI, 2003; Samoli et al., 2003; Vogt et al., 2003; 
Mar et al., 2005; Samoli et al., 2005), we are unaware of any such applications involving 
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human metabolism or exposure-biomarker relationships.  Since GLM+NS models are 
flexible and robust, they offer great promise as tools for investigating human metabolites and 
other biomarkers of environmental toxicants.   
We used GLM+NS models to test for effects upon metabolite levels of several 
demographic factors (Table 3.2).  Of the covariates considered, only age and/or gender 
consistently showed significant effects among the 5 metabolites, after adjustment for benzene 
exposure.  Male subjects had exposure-adjusted metabolite levels that were about 20% lower 
than those of females.  (For example, males had 100× ( )0 2091 −− .e = 18.9% less HQ than 
females at a given exposure level).  Likewise, levels of 4 metabolites (MA, SPMA, PH, and 
HQ) diminished with age, at rates between 1.1 and 1.9 percent per year of life (Table 3.2).  
This range is the same as that reported for albumin adducts of benzene oxide and 1,4-
benzoquinone in a different sample of Chinese workers (Rappaport et al., 2002).  Although 
we expected that co-exposure to toluene (a competitive inhibitor of benzene for CYP 
metabolism) would affect metabolite levels, this was not the case, possibly due to the 
relatively low toluene concentrations in our study (median, 3.29 ppm ; 10th–90th percentile 
range, 0.012– 21.9 ppm n =326).  
After adjusting for benzene exposure, smoking subjects had about 40% higher levels of 
HQ and CA than nonsmokers (Table 3.2).  Since significant smoking effects were not 
observed for MA, SPMA and PH, we attribute this result to the uptake of HQ and CA per se 
from cigarette smoke (Hecht et al., 1981; IARC., 1986; McDonald et al., 2001; McCue et al., 
2003).  To quantify the contributions of HQ and CA derived per cigarette, we regressed the 
logged levels of HQ and CA on self-reported smoking frequencies in 131 control subjects, 
who provided this information.  This resulted in the following relationships:  
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ln(HQ, M) = 1.79 + 0.021(cig./d) (p < 0.01) and ln(CA, M) = 2.41 + 0.011(cig./d) (p = 
0.19).  Based upon these models, smoking 20 cigarettes would result in 52% more HQ [i.e., 
100×(1 - e(0.021×20))%] and 20% more CA than observed in nonsmoking control subjects. 
Although background-adjusted levels of all metabolites increased monotonically with 
benzene exposures up to about 30 ppm (Figure 3.3A), the molar fractions for PH, HQ and 
MA changed continuously with increasing air concentrations (Figure 3.3B) while those for 
CA and SPMA remained relatively constant.  This indicates that the competing CYP-
mediated pathways (Figure 3.1) were sensitive to the air levels of benzene inhaled by these 
subjects.  Below 20 ppm, molar fractions of HQ and MA increased with exposure, while 
those of PH decreased with exposure; above 20 ppm the opposite behavior was observed.  
Since production of HQ and MA was preferred to that of PH (below 20 ppm), we infer that 
PH and oxepin were either higher-affinity substrates than benzene for the particular CYP 
enzymes or were more accessible to these enzymes.  This conjecture is supported by studies 
showing that KM values for CYP-mediated metabolism of PH and oxepin were smaller than 
those of benzene in tissues from humans and/or animals (Medinsky et al., 1989; Schlosser et 
al., 1993; Snyder et al., 1993; Seaton et al., 1994).  Above 20 ppm, the second CYP 
oxidation steps, leading to HQ and MA, appear to have become increasingly saturated; this 
led to the buildup of PH and, to lesser extents, of CA and SPMA (other products of a single 
CYP-oxidation step) (Henderson et al., 2005a).  
Using mean trends from the NS models (Figure 3.4) we investigated dose-specific levels 
(M/ppm) of the 5 benzene metabolites and their sum (total metabolites).  The spaghetti plots 
from the 500 bootstrap realizations were dense along the observed mean trends, and 
interquartile ranges were relatively small.  Wide 95% confidence bands were observed below 
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about 0.1 ppm, due to the large relative errors from background subtraction in this region, 
particularly for PH, HQ and CA, which have important dietary and endogenous sources 
(McDonald et al., 2001; National Library of Medicine, 2003; EPA, 2006).  However, given 
the narrow interquartile ranges, our conclusions regarding the mean trends should be 
reasonable.  Overall, expected median values of dose-specific levels of total metabolites 
decreased about 9-fold between 0.03 and 88.9 ppm of benzene.  For benzene exposures 
below 20 ppm, the decreasing trends were more pronounced for PH and CA (7 – 11-fold) 
than for HQ and MA (2 – 3-fold), reflecting the apparent preference for metabolism of the 
latter metabolites at low exposures (described above).  At benzene exposures above 20 ppm, 
the trends accelerate downwards for MA and HQ and turn upwards for PH and CA, 
consistent with results from previous investigations of workers heavily exposed to benzene 
(Rothman et al., 1998; Waidyanatha et al., 2001; Waidyanatha et al., 2004).  The mean trend 
for the minor product, SPMA, increased over the observed range of exposures and, therefore, 
displayed completely different behavior than those of the major metabolites.   
Interestingly, about 90% of the reductions in dose-specific metabolite levels occurred 
below about 3 ppm for each major product.  This behavior was unexpected, given current 
toxicokinetic models which indicate that saturable benzene metabolism should not be 
observed below about 3 – 10 ppm in humans (Travis et al., 1990; Rappaport et al., 2005).  
Thus, our results suggest that current toxicokinetic models for benzene are not accurate for 
air concentrations below 3 ppm.   
It is also important to point out that human health risks associated with benzene 
exposure are based upon linear extrapolation from epidemiology studies involving workers 
exposed, on average, to air concentrations of tens to hundreds of ppm (Hayes et al., 1997; 
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Savitz and Andrews, 1997).  Our results indicate that persons exposed to air concentrations 
less than 0.1 ppm metabolize benzene about 9-times more efficiently that such heavily 
exposed workers (see Figure 3.4F).  Since the toxic effects of benzene are thought to result 
from metabolism, this suggests that the health risks associated with low and very low 
benzene exposures can be considerably greater than those currently predicted from 
occupational studies.  
  
  
CHAPTER 4.   
GENETIC POLYMORPHISMS AND BENZENE 
METABOLISM IN HUMANS EXPOSED TO A WIDE 
RANGE OF AIR CONCENTRATIONS 
[Kim S, Lan Q, Waidyanatha S, Johnson AB, Vermeulen R, Smith MT, et al. 
Pharmacogenet Genomics 2006 (submitted)]  
 
4.1. Abstract 
Using generalized linear models with natural-spline smoothing functions, we detected 
effects of particular metabolizing genes and gene-environment interactions on levels of 
benzene metabolites in 250 benzene-exposed and 136 control workers in Tianjin, China (for 
all subjects the median exposure was 0.694 ppm and the 10th and 90th percentiles were 0.006 
and 7.79 ppm, respectively).  We investigated 5 urinary metabolites [E, E-muconic acid 
(MA), S-phenylmercapturic acid (SPMA), phenol (PH), catechol (CA) and hydroquinone 
(HQ)] and 9 SNPs of metabolizing genes [cytochrome P450 2E1 (CYP2E1), NAD(P)H: 
quinone oxidoreductase (NQO1), microsomal epoxide hydrolase (EPHX1), glutathione-S-
transferases (GSTT1, GSTM1 and GSTP1) and myeloperoxidase (MPO)].  After adjusting 
for covariates, including gender, age and smoking status, NQO1*2 affected all five 
metabolites, CYP2E1 (-1054C>T) affected all metabolites except CA, EPHX1 (Ex3-28T>C 
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or Ex4+52A>G) affected CA and SPMA, and GSTT1 and GSTM1 affected SPMA.  
Significant interactions were also detected between benzene exposure and all four genes and 
between smoking status and NQO1 and EPHX1.  No significant effects were detected for 
GSTP1 or MPO.  Results generally support prior associations between benzene 
hematotoxicity and specific gene mutations, confirm earlier evidence that GSTT1 affects 
production of SPMA, and provide additional evidence that SNPs of NQO1, CYP2E1, and 
EPHX1 are functional in humans exposed to benzene.   
 
4.2. Introduction 
Benzene is an important industrial chemical that is ubiquitous in the environment due to 
vaporization from petroleum products and combustion of hydrocarbons (IARC, 1982; 
Wallace, 1996; ATSDR, 1997).  Occupational exposures to benzene can cause blood 
disorders, including aplastic anemia, myelodysplastic syndrome, and acute myelogenous 
leukemia (Aksoy, 1985; Yin et al., 1989; Rothman et al., 1996a; Savitz and Andrews, 1997).  
Significant decreases in the numbers of white blood cells and platelets have been reported in 
workers exposed to less than one ppm of benzene (Lan et al., 2004).  Although these toxic 
effects are related to metabolism of benzene in the liver, the particular metabolite(s) that 
damage bone marrow cells and the mode of toxic action are subjects of debate (Ross, 2000) 
(Snyder, 2000a; Snyder, 2002). 
Since the pioneering work of Parke and Williams’ (Parke and Williams, 1953b; Parke 
and Williams, 1953a), the metabolism of benzene has been extensively investigated 
(reviewed in (Ross, 2000) (Snyder, 2002)).  The major metabolic pathways, shown in Figure 
4.1, begin with cytochrome P450 CYP2E1-mediated oxidation of benzene to benzene oxide 
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(BO), which is in equilibrium with its tautomer, oxepin.  BO-oxepin is the source of all other 
major metabolites, namely, phenol (PH), E,E-muconic acid (MA), hydroquinone (HQ), and 
catechol (CA), as well as the minor product, S-phenylmercapturic acid (SPMA).  All of these 
metabolites are excreted in urine, either free or in conjugated form.  Additional metabolism 
of the primary metabolites produces additional electrophilic species, including the 
muconaldehydes (from CYP oxidation of oxepin followed by ring-opening), and 1,2- and 
1,4-benzoquinone (BQ) (from spontaneous or peroxidase-mediated oxidation of CA and HQ, 
respectively).   
As shown in Figure 4.1, numerous enzyme systems are involved in the metabolism of 
benzene and its metabolites.  In addition to the CYP oxidations of benzene (to BO), oxepin 
(to the muconaldehydes and ultimately MA) and PH (to HQ) (Gilmour et al., 1986; Snyder 
and Hedli, 1996; Witz et al., 1996), microsomal epoxide hydrolase (EPHX) catalyzes the 
hydrolysis of BO to initiate the CA pathway (Penning and Sharp, 1990; Snyder and Hedli, 
1996), various glutathione-S-transferases (GSTs) catalyze production of SPMA (Verdina et 
al., 2001), and NAD(P)H: quinone oxidoreductase (NQO1) and peroxidases (notably 
myeloperoxidase (MPO)) are thought catalyze  transformations between CA and HQ and the 
corresponding quinones (1,2-BQ and 1,4-BQ, respectively) (Snyder and Hedli, 1996; Smith, 
1999; Snyder, 2002; Ross, 2005).   
It has been speculated that polymorphic genes of the above enzymes predispose some 
individuals to benzene toxicity through metabolism (Seaton et al., 1994; Rothman et al., 
1997; Nedelcheva et al., 1999).  In particular, individuals with wild-type MPO (more active) 
and a variant of NQO1 (less active) were found to be at greater risk of reduced numbers of 
white blood cells at low levels of benzene exposure (Lan et al., 2004).  Yet, although GSTT1 
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polymorphisms have been shown to affect production of the minor metabolite SPMA 
(Sorensen et al., 2003; Sorensen et al., 2004; Qu et al., 2005), there is only sketchy evidence 
that the major metabolites (PH, MA, HQ, and CA) are affected by polymorphic forms of 
CYP2E1, EPHX, NQO1 or MPO. 
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Figure 4.1. Simplified metabolic scheme for benzene showing major pathways and 
metabolizing genes. 
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A major difficulty in elucidating the connections between genotypes of metabolizing 
genes and the corresponding in vivo phenotypes has been the inability to control for the 
effects of benzene exposure, as well as of important physiological and lifestyle factors, in 
observational studies.  Indeed, the relationship between metabolite levels and benzene 
exposure is highly nonlinear and is significantly affected by gender, smoking status, and 
body mass index (BMI) (Kim et al., 2006b; Kim et al., 2006a).  Using generalized linear 
models (GLM) with natural spline (NS) smoothing functions, we were able to elucidate the 
effects of gender, BMI, and smoking status, after adjustment for benzene exposure (between 
0.01 and 88.9 ppm) in a sample of 386 benzene-exposed and control workers in Tianjin, 
China (Kim et al., 2006a).  In the current paper we extend our application of GLM+NS 
models to investigate the effects of polymorphic forms of CYP2E1, EPHX, NQO1, MPO, 
and GSTs on urinary levels of PH, MA, HQ, CA and SPMA in these workers.    
 
4.3. Materials and Methods 
4.3.1. Study Population, and Air and Biological Sample Collection 
Exposed and control subjects were recruited with informed consent from two shoe-
making factories and three clothes-manufacturing factories, respectively, in Tianjin, China as 
described in Lan et al. (Lan et al., 2004), and benzene exposure and workplace 
characteristics have been previously described in detail (Lan et al., 2004; Vermeulen et al., 
2004; Kim et al., 2006b).  After excluding 4 control subjects, who were missing values of 
metabolite and/or exposure measurements, the samples included 250 exposed subjects and 
136 control subjects.  Exposed and control subjects were frequency matched by gender.  
Table 4.1 shows summary statistics for the gender, age and smoking status of participants.  
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Methods of sampling air and urine were also previously described (Lan et al., 2004; 
Vermeulen et al., 2004; Kim et al., 2006b).  Briefly, personal full-shift air measurements 
were matched with post-shift urine samples from exposed and control workers.  Of the 386 
subjects in this analysis, 139 had repeated measurements of air and urine, making a total of 
617 matched air/urine samples.  Among subjects with repeated measurements, the median 
number of paired air and urine samples was three (range: 2 – 4).  Information about height, 
weight, smoking status and other relevant factors were obtained by questionnaire (Lan et al., 
2004).  
This study was approved by the Institutional Review Boards of the University of North 
Carolina, the University of California, Berkeley, the U.S. National Cancer Institute and the 
Chinese Academy of Preventive Medicine. 
 
Table 4.1. Demographics, benzene exposure and other characteristics of study 
population (n = 386). 
  Female   Male   All 
Occupational exposure*               
    Controls 84 (61.8%)   52 (38.2%)   136 (100.0%) 
    Exposed 164 (65.6%)   86 (34.4%)   250 (100.0%) 
Benzene exposure†                 
    Air benzene (ppm) 0.770 (0.006–7.74)   0.616 ( 0.006–9.21)   0.694 (0.006–7.79) 
Age (y)† 31 (21–44)   24 (20–39)   28 (21–43) 
BMI (kg/m2)† 21.8 (18.7–27.0)   22.0 (18.4–26.5)   21.9 (18.7–26.9) 
Current smoking status*               
    Non-smoker 240 (81.4%)   55 (18.6%)   295 (100.0%) 
    Smoker 8 (8.8%)   83 (91.2%)   91 (100.0%) 
Toluene exposure*                 
    Low  (1.79 ppm) 130 (67.4%)   63 (32.6%)   193 (100.0%) 
    High (>1.79 ppm) 118 (61.1%)   75 (38.9%)   193 (100.0%) 
*
 Number (percent). † Median (10th–90th percentiles) 
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4.3.2. Measurements of Air and Urinary Analytes 
Measurements of analytes in air and urine were described previously (Vermeulen et al., 
2004; Kim et al., 2006b; Kim et al., 2006a).  Briefly, benzene and toluene were measured in 
air using passive personal monitors (Organic Vapor Monitors, 3M, St. Paul, MN) followed 
by solvent desorption and gas chromatography (Vermeulen et al., 2004).  Air measurements 
of benzene and toluene were below limits of detection (LOD, nominally 0.2 ppm for benzene 
and 0.3 ppm for toluene) and were missing for all control subjects and for some exposed 
subjects (missing values, n = 23; measurements below the LOD for exposed subjects: n = 70 
for benzene, n = 67 for toluene).  Air levels were predicted in these censored and missing air 
samples from the corresponding urinary levels of benzene and toluene, as described 
previously for benzene (Kim et al., 2006a).  As summarized in Table 4.1, the median air 
level of benzene was 0.694 ppm, the 10th percentile level was 0.006 ppm and the 90th 
percentile was 7.79 ppm.  The median air level of toluene was 1.79 ppm.   
Urinary benzene was determined by gas chromatography-mass spectrometry (GC-MS) 
using head-space solid-phase microextraction according to Waidyanatha et al. (Waidyanatha 
et al., 2001).  Urinary PH, CA, HQ, MA, and SPMA were measured as trimethylsilylether 
derivatives by GC-MS, after digestion of urine to release conjugates, according to 
Waidyanatha et al. (Waidyanatha et al., 2004).  Quantification of all urinary analytes was 
based on peak areas relative to the corresponding isotopically labeled internal standards.  The 
minor metabolite, SPMA, was not detected in 30 urine specimens; a value of LOD/2 = 0.591 
nM was imputed to these samples (Hornung and Reed, 1990). 
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4.3.3. Genotyping 
We selected 9 single nucleotide polymorphisms (SNPs) in 7 genes coding for enzymes 
that presumably play a role in benzene metabolism, based on the evidence of functionality in 
experimental or human studies (described in the discussion section).   
 
Table 4.2. Distributions of SNPs among subjects in the study. 
Gene name 
SNP region 
SNP ID 
(Notes) 
Genotype 
No. 
subjects (%) 
Presumed 
phenotype Reference 
CYP2E1 C/C 239 (62.1) Active (Marchand et al., 1999) 
-1054C>T C/T 127 (33) Less active  
Rs2031920 T/T 19 (4.9) Least active  
(ascribed to RsaI)      
NQO1 C/C 105 (27.3) Active (Ross et al., 2000) 
Ex6+40C>T C/T 173 (44.9) Less active  
Rs1800566 T/T 107 (27.8) Inactive  
(NQO1*2)      
NQO1 C/C 359 (93.7) Active (Pan et al., 1995) 
Ex4-3C>T C/T 24 (6.3) Less active (Eguchi-Ishimae et al., 2005) 
Rs4986998 T/T 0 (0.0) Least active  
(NQO1*3)      
MPO G/G 297 (77.3) Active (Williams, 2001) 
-642G>A G/A 76 (19.8) Less active  
Rs2333227 A/A 11 (2.9) Least active  
GSTM1 +/+ 28 (7.4) Conjugator (Hsieh et al., 1999) 
del{GSTM1} +/- 141 (37.2)   
n/a -/- 210 (55.4) Null  
GSTT1 +/+ 33 (8.6) Conjugator (Hsieh et al., 1999) 
del{GSTT1} +/- 187 (48.8)   
n/a -/- 163 (42.6) Null  
GSTP1 A/A 224 (58.6) Conjugator (Morgan and Smith, 2002) 
Ex5-24A>G A/G 142 (37.2)   
Rs947894 G/G 16 (4.2) Less active  
EPHX1 T/T 143 (38) Normal (Jourenkova-Mironova et al., 2000) 
Ex3-28T>C T/C 176 (46.8)  (Lodovici et al., 2004) 
Rs1051740 C/C 57 (15.2) Slow metabolizer  
(Y113H)      
EPHX1 A/A 302 (79.9) Normal (Jourenkova-Mironova et al., 2000) 
Ex4+52A>G A/G 71 (18.8)  (Lodovici et al., 2004) 
Rs2234922 G/G 5 (1.3) Rapid metabolizer  
(H139R)      
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As summarized in Table 4.2, the following SNPs were chosen: CYP2E1 (-1054C>T, 
contributes to CYP2E1*5B, aka -1053), two alleles of NQO1 [NQO1*2 (Ex6+640C>T) 
bearing P187S and NQO1*3 (Ex4-3C>T) bearing R139W], MPO (-642G>A, aka -463 
promoter variant), GSTM1, GSTT1, and GSTP1 (Ex5-24A>G) bearing I105V, and two alleles 
of EPHX1 (Ex3-28T>C and Ex4+52A>G) bearing Y113H and H139R, respectively.  
Genotyping was performed with an ABI 7900HT detection system using TaqMan end point 
reads as described on the website, http://snp500cancer.nci.nih.gov (Packer et al., 2004).  The 
numbers of subjects with each SNP of the various metabolizing genes are summarized in 
Table 4.2.  Quality control procedures have been described previously (Lan et al., 2005). In 
brief, blind replicate samples were randomly interspersed throughout the study sample plates 
and showed intrasubject agreement >99% for all genotype assays.  
4.3.4. Statistical Analyses   
Relationships between levels of the urinary metabolites and the corresponding air 
concentrations of benzene were examined using GLM+NS models, as previously described 
(Kim et al., 2006a).  The smoothing functions were based upon 5-knot models for all 
metabolites, after comparing NS models with 5 – 7 knots by visual inspection and corrected 
Akaike’s Information Criteria (AICc) (Burnham et al., 2002).  (The candidate knots in the 5-
knot model were 0.001, 0.009, 0.512, 1.54 and 11.3 ppm of benzene in air, corresponding to 
the 5th, 27.5th, 50th, 72.5th and 95th percentiles (Harrell, 2001), respectively).  To avoid 
overparameterization, non-significant knots for each exposure-metabolite relationship were 
removed by stepwise elimination using a value of p < 0.10 for retention (PROC REG of 
SAS) (Kim et al., 2006a).  For subjects with repeated measurements of air and urine, the 
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estimated geometric mean air and metabolite concentrations were used in all statistical 
analyses.   
After establishing NS smoothing functions for each metabolite, we used GLM to 
investigate effects of SNPs and their interactions with benzene exposure and smoking status, 
after adjusting for the following covariates: gender (0, female; 1, male), age (centered around 
the estimated mean value of 29.8 y, n = 386), smoking status (0, nonsmoker; 1, smoker), 
BMI (centered around the estimated mean value of 22.5 kg/m2, n = 384).  We also 
investigated effects of toluene exposure (0, low exposure; 1, high exposure; median as a cut-
off point, 1.79 ppm) on levels of each metabolite.   
Potential effects of SNPs were screened in two stages to explore exposure-related 
interactions and smoking-related interactions, respectively.  In both stages, the number of 
effects was restricted to less than 10% of observations to avoid overfitting.  Then, important 
main effects and interactions were pooled from the two stages to build final models.  Every 
candidate model for a given benzene metabolite was sorted by AICc, and the final model was 
selected from the best and second-best candidates, using the following criteria: ∆AICc, 
evidence ratio, and the significance and biologically plausible of explanatory variables 
(Burnham et al., 2002).  Modeling was performed using PROC GLMSELECT of SAS/STAT 
with the selection/stop option of AICc (Burnham et al., 2002; SAS Institute., 2005).  
In coding each SNP, the homozygous wild-type was defined as the reference group.  
Data for EPHX1 (Ex4+52A>G), variant homozygotes and heterozygotes were combined in 
the analysis because the former contained only five subjects (1.3%) (Lan et al., 2005).  Tests 
for Hardy-Weinberg equilibrium (HWE) among subjects were conducted based on observed 
genotype frequencies using PROC ALLELE of SAS/GENETICS (using a Pearson’s χ2 test 
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with one degree of freedom).  All genotypes were in HWE except MPO (-642G>A) (p = 
0.04).  The quality control data were rechecked and the precision of genotyping for this SNP 
in blind replicates was confirmed, so this slight departure from HWE is likely due to chance.  
Tukey-Cramer adjustment was carried out for multiple comparisons of least-squares means 
among SNPs in the final models.   
All statistical analyses were performed using SAS software for Windows ver. 9.13 (SAS 
Institute, Cary, NC).   
 
4.4. Results 
4.4.1. GLM+NS Models and Covariate Effects 
The following NS smoothing functions were used for the 5 benzene metabolites: 
MA: 3 3
, 1 3 +E[ln( ) | ln( )] = 0.754 + 0.127[ln( )] + 0.005[ln( )- ]  0.019[ln( )- ]MA j j j j jY X X X Xξ ξ+ − , 
SPMA: 3 3
, 1 2 +E[ln( ) | ln( )] = -6.65  0.119[ln( )] + 0.030[ln( )- ]  0.040[ln( )- ]SPMA j j j j jY X X X Xξ ξ+− − ,  
PH: 3
, 2E[ ln( ) | ln( )]= 4.38 + 0.053[ln( )] + 0.005[ln( )- ]PH j j j jY X X X ξ + , 
CA: 3 3
, 1 2E[ ln( ) | ln( )]= 3.02 + 0.098[ln( )]  0.005[ln( )- ] + 0.011[ln( )- ]CA j j j j jY X X X Xξ ξ+ +− , and 
HQ: 3 3
, 1 5 +E[ ln( ) | ln( )]= 1.72 0.016[ln( )] + 0.004[ln( )- ]  0.123[ln( )- ]HQ j j j j jY X X X Xξ ξ+− − . 
where E[ln(Ym,j)|ln(Xj)] is the conditional mean value of ln(Ym,j) representing the natural-
log transform of the level of the mth metabolite level in the jth subject at ln(Xj), the 
corresponding (logged) air concentration of benzene (ppm), and ξi is the location of the ith 
knot (in log-scale of benzene exposure): ξ1 = ln(0.001 ppm), ξ2 = ln(0.009 ppm), ξ3 = 
 70 
ln(0.512 ppm), ξ4 = ln(1.54 ppm), ξ5 = ln(11.3 ppm).  The function 3[ln( ) ]j iX ξ +−  equals 
3[ln( ) ]j iX ξ−  for positive values and equals zero otherwise. 
Final GLM+NS models are summarized in Tables 4.3 – 4.7 for the 5 benzene 
metabolites.  Referring to the non-genetic effects, results are similar to those reported 
previously without adjustment for SNPs (Kim et al., 2006a).  Female subjects had higher 
levels of MA, PH, CA and HQ than males (p < 0.05) and younger subjects (below 30 yr) had 
higher levels of MA, PH and HQ than older subjects.  Smokers generally had higher levels of 
benzene metabolites than nonsmokers, but the relationships were complicated by gene-
smoking interactions for SPMA, PH and CA.  No significant effects were observed on any of 
the benzene metabolites for either BMI or co-exposure to toluene.   
 
Table 4.3. Parameter estimates for the final model of E,E-muconic acid (MA). [The 
dependent variable was the natural logarithm of the MA concentration, (M); n = 382, 
R2=85.0%] 
Independent variable Description Parm. est. Std. err. p-value Cumulative ∆R2 (%) 
Intercept   0.937 0.197 <.0001   
Age Centered at mean (29.8 yr) -0.017 0.005 <0.001   
Sex Male -0.276 0.099 0.005   
Smoking Smoker 0.177 0.107 0.099   
BMI Centered at mean (22.5 kg/m2) 0.019 0.011 0.076   
ln(Xj) × *1/*2, less active -0.076 0.027 0.005 ln(Xj)×NQO1*2 
ln(Xj) × *2/*2, least active -0.070 0.029 0.016 
0.37 
NQO1*2 *1/*2, less active -0.174 0.099 0.081 
  
*2/*2, least active -0.184 0.110 0.094 
0.38 
ln(Xj) × C/T, less active 0.001 0.024 0.955 ln(Xj) × CYP2E1 
ln(Xj) × T/T, least active -0.150 0.042 <0.001 
1.00 
CYP2E1 (-1054C>T) C/T, less active 0.037 0.087 0.667 
  
T/T, least active -0.406 0.191 0.034 
1.01 
Legend: ln(Xj) represents the natural logarithm of the air benzene concentration (ppm) in the jth subject. 
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Table 4.4. Parameter estimates for the final model of S-phenyl mercapturic acid 
(SPMA). [The dependent variable was the natural logarithm of the SPMA concentration, 
(M); n = 365, R2=82.0%] 
Independent variable Description Parm. est. Std. err. p-value Cumulative ∆R2 (%) 
Intercept   -4.811 0.685 <.0001   
Age Centered at mean (29.8 yr) -0.012 0.009 0.161   
Sex Male -0.280 0.181 0.123   
Smoking Smoker -0.690 0.337 0.042   
BMI Centered at mean (22.5 kg/m2) -0.025 0.019 0.189   
GSTM1 +/-,  less active -0.458 0.254 0.072 0.31 
  
-/-,  null -0.590 0.248 0.018  
ln(Xj) × EPHX1 ln(Xj) × (A/G or G/G, faster) 0.101 0.051 0.049 0.55 
EPHX1 (Ex4+52A>G) A/G or G/G, faster 0.234 0.187 0.213 0.56 
ln(Xj) × *1/*2, less active -0.149 0.049 0.003 0.98 ln(Xj)×NQO1*2 
ln(Xj) × *2/*2, least active -0.069 0.053 0.199  
ln(Xj) × C/T, less active 0.114 0.045 0.011 1.44 ln(Xj) × CYP2E1 
ln(Xj) × T/T, least active -0.038 0.076 0.617  
C/T, less active 0.146 0.159 0.357 1.50 
CYP2E1 (-1054C>T) 
T/T, least active -0.480 0.345 0.164  
Smoker × *1/*2, less active 1.108 0.385 0.004 1.94 
Smoking×NQO1*2 
Smoker × *2/*2, least active 1.041 0.413 0.012  
NQO1*2 *1/*2, less active -0.654 0.203 0.001 2.01 
  
*2/*2, least active -0.646 0.227 0.005  
ln(Xj) × +/-, less active -0.035 0.069 0.614 2.63 ln(Xj) × GSTT1 
ln(Xj) × -/-,  null -0.143 0.070 0.041  
GSTT1 +/-,  less active -0.592 0.251 0.019 4.86 
  
-/-,  null -1.444 0.258 <.0001  
Legend: ln(Xj) represents the natural logarithm of the air benzene concentration (ppm) in the jth subject. 
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Table 4.5. Parameter estimates for the final model of phenol (PH). [The dependent 
variable was the natural logarithm of the PH concentration, (M); n = 382, R2=64.8%] 
Independent variable Description Parm. est. Std. err. p-value Cumulative ∆R2 (%) 
Intercept   4.645 0.100 <.0001   
Age Centered at mean (29.8 yr) -0.010 0.004 0.014   
Sex Male -0.313 0.090 0.001   
Smoking Smoker -0.204 0.167 0.222   
BMI Centered at mean (22.5 kg/m2) 0.007 0.010 0.477   
Smoking×NQO1*2 Smoker × *1/*2, less active 0.311 0.192 0.106 
  
Smoker × *2/*2, least active 0.538 0.204 0.009 
0.67 
NQO1*2 *1/*2, less active -0.196 0.085 0.022 
  
*2/*2, least active -0.337 0.097 0.001 
1.31 
ln(Xj) × C/T, less active 0.026 0.022 0.230 ln(Xj) × CYP2E1 
ln(Xj) × T/T, least active -0.141 0.038 <0.001 
2.75 
CYP2E1 (-1054C>T) C/T, less active 0.037 0.079 0.640 
  
T/T, least active -0.613 0.174 0.001 
3.08 
Legend: ln(Xj) represents the natural logarithm of the air benzene concentration (ppm) in the jth subject. 
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Table 4.6. Parameter estimates for the final model of catechol (CA). [The dependent 
variable was the natural logarithm of the CA concentration, (M); n = 370, R2=57.2%] 
Independent variable Description Parm. est. Std. err. p-value Cumulative ∆R2 (%) 
Intercept   3.072 0.285 <.0001   
Age Centered at mean (29.8 yr) <0.001 0.004 0.997   
Sex Male -0.272 0.087 0.002   
Smoking Smoker 0.567 0.127 <.0001   
BMI Centered at mean (22.5 kg/m2) -0.007 0.009 0.448   
ln(Xj)×NQO1*2 ln(Xj) × *1/*2, less active -0.037 0.023 0.113 
  
ln(Xj) × *2/*2, least active -0.058 0.025 0.021 
0.67 
NQO1*2 *1/*2, less active -0.186 0.089 0.036 
  
*2/*2, least active -0.237 0.097 0.015 
0.96 
EPHX1 (Ex4+52A>G) A/G or G/G, faster 0.143 0.076 0.061 1.43 
ln(Xj) ×EPHX1 ln(Xj) × (T/C, slow) -0.039 0.021 0.063 
           (Ex3-28T>C) ln(Xj) × (C/C, slower) -0.069 0.028 0.014 
2.22 
Smoker × (T/C, slow) -0.163 0.156 0.299 
Smoking×EPHX1 
Smoker × (C/C, slower) -0.633 0.206 0.002 
3.32 
T/C, slow -0.019 0.086 0.827 
EPHX1 (Ex3-28T>C) 
C/C, slower 0.096 0.118 0.420 
3.36 
Legend: ln(Xj) represents the natural logarithm of the air benzene concentration (ppm) in the jth subject. 
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Table 4.7. Parameter estimates for the final model of hydroquinone (HQ). [The dependent 
variable was the natural logarithm of the HQ concentration, (M); n = 382, R2=72.6%] 
Independent variable Description Parm. est. Std. err. p-value Cumulative ∆R2 (%) 
Intercept   1.758 0.118 <.0001   
Age Centered at mean (29.8 yr) -0.011 0.004 0.006   
Sex Male -0.302 0.082 <0.001   
Smoking Smoker 0.473 0.089 <.0001   
BMI Centered at mean (22.5 kg/m2) -0.010 0.009 0.248   
*1/*2, less active -0.087 0.070 0.215 
NQO1*2 
*2/*2, least active -0.164 0.078 0.036 
0.34 
ln(Xj) × C/T, less active -0.008 0.020 0.676 ln(Xj) × CYP2E1 
ln(Xj) × T/T, least active -0.125 0.035 <0.001 
1.25 
C>T, C/T, less active -0.036 0.072 0.617 
CYP2E1 
C>T, T/T, least active -0.657 0.160 <.0001 
1.77 
Legend: ln(Xj) represents the natural logarithm of the air benzene concentration (ppm) in the jth subject. 
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4.4.2. Effects of Genetic Polymorphisms 
After adjusting for exposure and covariates, the following SNPs were found to 
significantly affect levels of the various metabolites, either as main effects or as interactions 
with benzene exposure and/or smoking: NQO1*2 for all metabolites, CYP2E1 for all 
metabolites except CA, GSTT1 and GSTM1 for SPMA, EPHX1 (Ex4+52A>G) for SPMA 
and CA, and EPHX1 (Ex3-28T>C) for CA.  The interaction between CYP2E1 and benzene 
exposure accentuated the effects of polymorphic forms of this gene on levels of MA, SPMA, 
PH and HQ among subjects exposed to higher benzene concentrations (Tables 4.3, 4.4, 5 and 
4.7).  For each of these metabolites, subjects having both variant alleles of CYP2E1 had 
lower metabolite levels than those with at least one wild-type allele.  For example, the 
relationships for HQ, shown in Fig. 4.2A, indicate that homozygous variants produced 
appreciably less metabolite than heterozygotes or homozygous wild types at air 
concentrations greater than 0.1 ppm (Tukey’s test, p <0.05).  Similar behaviors were 
observed for PH, where significant departure was observed above 0.2 ppm, and for MA 
above 2 ppm.  For SPMA, subjects with both variant alleles of CYP2E1 had the lowest 
metabolite levels at benzene concentrations between 0.02 and 88.9 ppm; however, the 
difference was not statistically significant (p > 0.05).  
Subjects with at least one variant allele of NQO1*2 had lower levels of all metabolites 
than homozygous wild types or heterozygotes (Tables 4.3 – 4.7).  This gene was also found 
to interact strongly with either benzene exposure (for MA, SPMA, and CA) and/or smoking 
status (for PH and SPMA).  These interactions with benzene exposure resulted in subjects 
with at least one variant allele of NQO1*2 having lower levels of CA above 0.8 ppm (p < 
0.05, Fig. 4.2B), lower levels of MA above 6 ppm (p < 0.05), and lower levels of HQ over 
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the entire range of exposure (significance, p < 0.1).  Among nonsmokers, subjects with 
NQO1*1/*1 produced more SPMA above 0.5 ppm (Fig. 4.2C, p < 0.05) and more PH over 
the entire range of exposure (Fig. 4.2D, p < 0.01) than subjects with NQO1*2/*2.  However, 
among smokers, these effects were diminished (Fig. 4.2D and 2E).  No effects were observed 
for NQO1*3 polymorphisms.   
Strong effects of GSTT1 and GSTM1 were observed on levels of SPMA, with 
homozygous variants producing the highest levels, followed by heterozygotes and 
homozygous null subjects (Table 4.4).  A significant interaction was also observed between 
benzene exposure and GSTT1 null subjects, such that these workers produced increasingly 
less SPMA at higher air concentrations (see Fig. 4.1E).  No effect of polymorphic forms of 
GSTP1 was observed on SPMA levels. 
Subjects with variant alleles of EPHX1 (Ex3-28T>C) had lower levels of CA, 
particularly among smokers, than homozygous wild types (see Table 4.6).  Due to the 
interaction of EPHX1 (Ex3-28T>C) with benzene exposure, this effect was accentuated 
among smokers at air concentrations above 0.8 ppm (p < 0.05) (Fig.4.1.F).  Subjects with at 
least one variant allele of EPHX1 (Ex4+52A>G) had higher CA levels than homozygous 
wild types (p = 0.06).  Interestingly, subjects with variant EPHX1 (Ex4+52A>G) also had 
higher levels of SPMA at benzene concentrations above 6 ppm (p < 0.1).  
No effects were observed for polymorphic forms of MPO. 
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Figure 4.2. Effects of genetic polymorphisms on urinary metabolites of benzene in 
humans (representative plots).  Each panel depicts effects of a particular SNP on levels of a 
given metabolite at versus the air concentration of benzene. 
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4.5. Discussion 
Although the hematotoxicity of benzene was reported more than a century ago, the 
mechanism is not yet fully understood (Ross, 2000).  It has been speculated that genetic and 
life-style factors can influence the toxic effects of benzene, but current evidence is far from 
conclusive (Ross, 2000; Snyder, 2000a; Snyder, 2002).  Rothman et al. reported that heavily 
benzene-exposed workers who were rapid chlorzoxazone metabolizers (a measure of 
CYP2E1 phenotype) and also possessed variant NQO1*2, were at elevated risk of benzene-
poisoning (Rothman et al., 1997).  More recently, Wan et al. (Wan et al., 2002) reported 
increased benzene poisoning in workers with variant NQO1*2 as well as in those with null-
type GSTT1 or CYP2E1 DraI, and Lan et al. (Lan et al., 2004) found lower white blood cell 
counts in workers with variants of NQO1*3 and MPO (-642G>A).  Other studies of 
polymorphisms among benzene-exposed workers reported that subjects with variant 
NQO1*2 had increased DNA single-strand breaks (Garte et al., 2005) but decreased 
aneuploidy (Kim et al., 2004) in peripheral lymphocytes.  The latter study also reported 
increased aneuploidy in benzene-exposed workers with null deletions of GSTT1 and GSTM1 
and with either of two CYP2E1 mutations (DraI or RsaI) (Kim et al., 2004).   
In the present study, we focused upon the effects of metabolizing genes on production of 
5 prominent metabolites (MA, SPMA, PH, CA and HQ).  These metabolites are not 
‘biological effect markers’ (Wogan, 1992) per se, but rather reflect primary metabolism in 
the liver, which appears to be a necessary prelude to benzene-induced toxicity in target 
organs (Ross, 2000; Snyder, 2002).  Previous attempts to link levels of benzene metabolites 
with polymorphic forms of metabolizing genes have been hampered by methodological and 
practical problems, including low benzene exposures (below 0.1 ppm) (Rossi et al., 1999; 
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Verdina et al., 2001; Sorensen et al., 2003; Sorensen et al., 2004; Fustinoni et al., 2005b), no 
measurements of air exposure (Hsieh et al., 1999; Wan et al., 2002; Avogbe et al., 2005; 
Testa et al., 2005), small numbers of subjects (Rossi et al., 1999; Sorensen et al., 2003; Kim 
et al., 2004; Sorensen et al., 2004), and difficulties in adjusting for covariates and nonlinear 
effects of exposure (Garte et al., 2005; Qu et al., 2005).  Since benzene exposures were 
typically very low in prior studies, only SPMA and MA (metabolites with high specificity for 
benzene) tended to be measured, and the only consistent effect of any SNP was that of lower 
SPMA levels in subjects with GSTT1 (null deletion) (Sorensen et al., 2003; Sorensen et al., 
2004; Qu et al., 2005).   
We detected several effects of SNPs on benzene metabolite patterns and interactions 
with benzene exposure that have not been reported previously (Tables 4.3 – 4.7).  Our study 
had substantially more subjects (386) and therefore greater power to detect such effects.  
Further strengths of our study were the ability to examine effects over a wide range of 
benzene exposures, determined in both benzene-exposed workers and controls, broad 
exploration of genetic variants in key genes, evaluation of all major benzene urinary 
metabolites, and use of GLM+NS models to adjust for exposure and covariates. At the same 
time, it is possible that some findings could be false positives, and these findings need to be 
replicated in other large studies. 
Subjects with NQO1*2 had lower levels of all 5 metabolites in our study.  Since NQO1 
catalyzes two- or four-election reductions of quinones (Nebert et al., 2002) (Traver et al., 
1997; Siegel et al., 1999; Ross et al., 2000), it is reasonable that levels of CA and HQ would 
be lower in subjects with NQO1*2 (less active), as we observed (Tables 4.6 and 4.7).  When 
combined with evidence that less active forms of NQO1 are associated with benzene 
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poisoning and DNA damage (Rothman et al., 1997; Wan et al., 2002; Lan et al., 2004; Garte 
et al., 2005), this finding is also consistent with speculation that 1,4-BQ and/or 1,2-BQ (the 
oxidized forms of HQ and CA, respectively) play roles in benzene-induced toxicity 
(Subrahmanyam et al., 1990; Subrahmanyam et al., 1991; McDonald et al., 1994; Snyder 
and Hedli, 1996; Snyder, 2002).  The fact that levels of the other three metabolites (MA, 
SPMA, and PH) were also lower among subjects with NQO1*2, suggests a more general role 
for NQO1.  Furthermore, the interaction effects between NQO1*2 and both benzene 
exposure and smoking status point to induction of NQO1 by reactive benzene metabolites or 
other reactive species (De Long et al., 1987; Moran et al., 1999; Ross, 2005).  Such induction 
could come about via either the antioxidant or xenobiotic response element in the NQO1 
promoter region (Ross, 1997; Smith, 1999; Jaiswal, 2000).  We found that that NQO1*2 but 
not NQO1*3 was associated with lower levels of benzene metabolites and that SNPs of MPO 
did not affect metabolism.  In contrast, we previously reported in the same study the presence 
of greater hematotoxicity in workers having the combination of NQO1*3 (C/T, less active) 
and MPO (A/A, more active) (Lan et al., 2004).  These contrasting results probably point to 
differences in the balance between NQO1 and MPO activities in liver (where metabolites are 
produced) and bone marrow (where metabolites are activated and deactivated in target 
hematopoietic cells).   
We observed significant effects of CYP2E1 variants on levels of MA, SPMA, PH, and 
HQ (Tables 4.3, 4.4, 5 and 4.7).  Controversy has surrounded the relationship between the 
genotype and phenotype of CYP2E1, an important gene that metabolizes small molecules of 
toxicological interest, including benzene (Hayashi et al., 1991; Lucas et al., 1995; Carriere et 
al., 1996; Kim et al., 1996; Nedelcheva et al., 1999; Wang et al., 1999; Wormhoudt et al., 
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1999; Carere et al., 2002; Le Marchand et al., 2002) (Ingelman-Sundberg et al., 2006) 
(Seaton et al., 1994; Seaton et al., 1995; Bolt et al., 2003).  There is some evidence that a 
variant type CYP2E1 (-1054C>T, also referred to as RsaI-), is associated with decreased 
CYP2E1 activity in vivo (Carriere et al., 1996; Powell et al., 1998; Marchand et al., 1999; 
Wang et al., 1999; Choi et al., 2003; Fustinoni et al., 2005b).  In the present study, we found 
that subjects with variant CYP2E1 (-1054C>T) produced lower levels of benzene metabolites 
at a given benzene exposure than homozygous wild types, and that the effect was accentuated 
at higher benzene levels due to gene-environment interactions.  The difference in metabolite 
levels between homozygous wild-types and homozygous variants was detected at benzene 
exposures in the range of 0.1 – 2 ppm for HQ, PH and MA (Tables 4.3, 4.5 and 4.7 and Fig. 
4.2A).  This interaction effect could point to induction of CYP2E1 (-1054C>T) by benzene 
exposure, or to more rapid saturation of metabolism among homozygous variant subjects 
(Nedelcheva et al., 1999).  Our results substantially support evidence from prior studies that 
CYP2E1 (-1054C>T) mutations functionally reduce the metabolism of CYP2E1 substrates. 
Subjects with variant alleles of EPHX1 (Ex3-28T>C) produced lower levels of CA in 
our study (Table 4.6 and Fig. 4.2F).  EPHX1 enzymes hydrolyze epoxides through the 
formation of hydroxyl alkyl-enzyme intermediates (Morisseau and Hammock, 2005).  
Although EPHX1 should logically be involved in benzene metabolism, notably in catalyzing 
BO to the dihydrodiol, the functional role of this enzyme has been ambiguous in benzene-
exposed subjects (Lovern et al., 1999; Nebert et al., 2002).  Two polymorphisms have been 
identified; one, in exon 3, decreased enzymatic activity 50% in vitro while the other, in exon 
4, increased activity 25% (Hassett et al., 1994).  Our findings that workers with variant 
allele(s) of EPHX1 (Ex3-28T>C) had lower levels of CA than homozygous wild-types while 
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those with at least one variant of EPHX1 (Ex4+52A>G) had marginally higher CA levels, 
support the in vitro results.  We also detected significant interactions between EPHX1 (Ex3-
28T>C) and both benzene exposure and smoking status.  The gene-smoking interaction 
tended to accentuate differences in CA levels between smoking subjects who had different 
alleles of EPHX1 (Ex3-28T>C) and to obscure effects among nonsmokers (Fig 4.2F).  The 
gene-exposure interaction produced differences in CA levels that could be distinguished 
between smokers having homozygous wild- and variant-types of EPHX1 (Ex3-28T>C) at 
benzene concentrations above one ppm.  Our results are intriguing in light of recent 
epidemiologic studies indicating that, among smokers, fast EPHX1 metabolizers had greater 
risks of colorectal adenomas (Cortessis et al., 2001; Huang et al., 2005) than slow 
metabolizers.  Interestingly, fast metabolizers of EPHX1 (Ex4+52A>G) also had marginally 
higher levels of SPMA at benzene concentrations above 6 ppm (p < 0.10).  Although the 
mechanism for production of SPMA is not yet established (Snyder et al., 1993; Henderson et 
al., 2005a),  the apparent effect of EPHX1 on SPMA levels may offer clues regarding 
formation of this minor benzene metabolite (Morisseau and Hammock, 2005).    
Among the GST isozymes, both GSTM1 and GSTT1 affected the production of SPMA 
(Table 4.4, Fig. 4.2B), with subjects having variant forms of these enzymes producing lower 
levels.  Of the two isozymes, GSTT1 produced more substantial effects, based upon evidence 
ratios (Burnham et al., 2002) (data not shown), and produced different profiles for each 
combination of alleles (Fig. 4.2B).  This finding of is consistent with previous studies 
(Sorensen et al., 2003; Sorensen et al., 2004; Qu et al., 2005).  No effect of GSTP1 was 
detected.  
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Finally, it is worth commenting upon the amounts of variability in metabolite levels that 
were explained by the observed genetic effects and the magnitudes of interindividual 
differences in metabolism that can be attributed to particular genes.  The GLM+NS models 
summarized in Tables 4.3 – 4.7 had R2 (%) values of 85.0 for MA, 82.0 for SPMA 64.8 for 
PH, 57.2 for CA and 72.6 for HQ, among which benzene exposure and non-genetic 
covariates explained between 53 and 84% of the variability in metabolite levels.  The 
corresponding percentages of variability explained by all significant genes and gene-
environment interactions were 1.0 for MA, 4.9 for SPMA 3.1 for PH, 3.4 for CA and 1.8 for 
HQ.  Thus, although many significant genetic effects were detected, they collectively 
contributed rather little to the explained variation in benzene metabolism.   
 
Table 4.8. SNP effects on benzene metabolites at various levels of benzene exposure. 
[Least-squares-mean ratios of variant/variant to wild/wild]. 
Air concentration (ppm) 
Metabolite SNP 
0.1 1 10 100 
CYP2E1 (-1054C>T) 0.941 0.666 0.472 0.333 
E,E-Muconic acid (MA) 
NQO1*2 0.976 0.832 0.708 0.603 
CYP2E1 (-1054C>T) 0.675 0.619 0.567 0.519 
EPHX1 (Ex4+52A>G) 1.00 1.26 1.59 2.01 
GSTT1 0.328 0.236 0.17 0.122 
GSTM1 0.554 0.554 0.554 0.554 
NQO1*2 (Nonsmokers) 0.614 0.524 0.448 0.382 
S-Phenylmercapturic acid 
(SPMA) 
NQO1*2 (Smokers) 1.74 1.48 1.27 1.08 
CYP2E1 0.75 0.542 0.392 0.283 
NQO1*2 (Nonsmokers) 0.714 0.714 0.714 0.714 Phenol (PH) 
NQO1*2 (Smokers) 1.22 1.22 1.22 1.22 
EPHX1 (Ex4+52A>G) 1.15 1.15 1.15 1.15 
NQO1*2 0.902 0.789 0.69 0.603 
EPHX1 (Ex3-28T>C, nonsmokers) 1.29 1.10 0.938 0.8 
Catechol (CA) 
EPHX1 (Ex3-28T>C, smokers) 0.685 0.584 0.498 0.425 
CYP2E1 (-1054C>T) 0.692 0.518 0.389 0.291 
Hydroquinone (HQ) 
NQO1*2 0.849 0.849 0.849 0.849 
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Regarding interindividual differences in metabolism that would be expected for a given 
SNP, Table 4.8 lists the ratios of predicted metabolite levels for homozygote variants to 
homozygous wild-types, based upon least-squares means of the models summarized in 
Tables 4.3 – 4.7.  These ratios represent the mean fold-ranges for variant/referent that would 
be expected for each SNP after adjusting for benzene exposure as well as covariates and 
other genetic effects.  Since several gene-environment interactions were identified, the tables 
cover benzene concentrations between 0.1 and 100 ppm and differentiate between smokers 
and nonsmokers when appropriate.  The values shown in Table 4.8 suggest that 
interindividual differences in metabolite production were generally rather modest, with most 
ratios lying between about 0.3 and 2.0.  Indeed, differences as great as 2- to 3.5-fold would 
only be anticipated for most metabolite-gene combinations when persons were exposed to 
very high benzene concentrations (100 ppm).  The exception to this rule is the large effect of 
GSTT1 on SPMA production, where homozygous referents would typically have SPMA 
levels 3- to 8-fold greater than those of homozygous variants.  This large fold range 
undoubtedly contributed to the earlier reports of significant effects of GSTT1 on SPMA 
levels (Sorensen et al., 2003; Sorensen et al., 2004; Qu et al., 2005). 
In conclusion, we used GLM+NS regression to detect numerous effects of particular 
metabolizing genes and gene-environment interactions on levels of benzene metabolites in 
386 Chinese workers.  Of the 9 SNPs investigated, NQO1*2 affected all five metabolites, 
CYP2E1 (-1054C>T) affected all metabolites but CA, EPHX1 (Ex3-28T>C or Ex4+52A>G) 
affected CA and SPMA, and GSTT1 and GSTM1 affected SPMA.  Significant interactions 
were detected between benzene exposure and all four genes and between smoking status and 
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NQO1 and EPHX1.  Results are generally consistent with prior reports of associations 
between benzene hematotoxicity and specific gene mutations and provide additional 
evidence regarding functionality of SNPs of NQO1, CYP2E1, and EPHX1 in humans 
exposed to benzene.  
  
  
CHAPTER 5.   
DISCUSSION AND CONCLUSIONS 
 
5.1. Summary and Conclusions 
Although the toxicity of benzene has been linked to its metabolites, the dose-related 
production of metabolites is not well understood in humans, particularly at low exposure 
levels. The present study was intended to elucidate the profiles of the main benzene 
metabolites in humans exposed to a wide range of benzene levels, and the effects of genetic 
and other factors upon metabolite levels. In order to do so, we analyzed a dataset containing 
air and metabolite levels along with personal information (including SNPs of key metabolic 
enzymes) from 389 subjects exposed to benzene in either workplace or general environment.  
5.1.1. Dose-related Patterns of Human Benzene Metabolism 
As exposure increased, the levels of benzene metabolites also increased. We used step-
functions to depict nominal exposures which were associated with a statistically significant 
increase in metabolite levels for subjects grouped by their exposure levels (n=30 per group). 
While there were marginal increases in MA, PH, CA and HQ at air benzene levels as low as 
0.02 ppm, levels of benzene metabolites were demonstrably different from background levels 
at about 0.2 ppm for MA and SPMA, 0.5 ppm for PH and HQ, and 2 ppm for CA (Fig. 2.2).  
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After adjustment for the background levels of benzene, MA, PH, CA and HQ showed 
significant downward trends of dose-related production [i.e., metabolite levels per ppm of 
benzene], whereas SPMA had an upwards trend between 0.027 and 15.4 ppm. The transitions 
were particularly accentuated at lower exposure (0.027 – 0.274 ppm), where a 16-fold 
reduction for CA, 4.4-fold for PH, 1.8-fold reduction for MA and 1.6-fold reduction for HQ.  
Thus, it appears that metabolism shifted away from CA and PH at low doses in favor of MA 
and HQ, which are the only major benzene metabolites requiring two CYP oxidations (Figure 
2.1). When exposures exceeded about one ppm, the dose-related profiles of PH, MA, HQ, 
and CA became quasi-parallel, suggesting that metabolism of benzene to BO had become 
rate-limiting.     
5.1.2. Modeling Human Metabolism of Benzene 
In order to verify the dose-related production of benzene metabolites, we needed a 
statistical model to address covariate effects on metabolites after adjustment for the nonlinear 
relationship between urinary metabolites and air benzene. From this perspective, a GLM+NS 
model was constructed. Based on analysis of the molar fractions of 5 major benzene 
metabolites (Fig.3.3B), CYP-mediated metabolic pathways favored MA and HQ below 20 
ppm and favored PH above 20 ppm. Mean trends of dose-specific levels (M/ppm benzene) 
of MA, PH, HQ, and CA decreased with increasing benzene exposure. Noticeably, about 
90% of the reductions in dose-specific levels (from 0.03 to 88.9 ppm) occurred below about 
3 ppm for each major metabolite. GLM+NS model also allowed us to detect significant 
effects of gender, age and smoking status on benzene metabolites. The level of each 
metabolite was about 20% or higher in females. Likewise, the levels of 4 metabolites (MA, 
SPMA, PH, and HQ) diminished with age, at rates between 1.1 and 1.9 percent per year of 
 88 
life. The levels of HQ and CA were greater in smoking subjects (Table 3.2).  Overall, these 
results indicate that benzene metabolism is highly nonlinear with increasing benzene 
exposure above 0.03 ppm (even after adjustment of background metabolites of benzene). 
Therefore, current human toxicokinetic models may not accurately predict benzene 
metabolism below 3 ppm.     
5.1.3. Genetic Polymorphisms and Benzene Metabolism in Humans 
We extended the GLM+NS model  to investigate the effects of genetic polymorphisms 
of key enzymes for benzene metabolism including CYP2E1, NQO1, MPO, GSTs and 
EPHX1, after adjustment for age, gender, BMI and smoking status. The following SNPs 
showed significant effects on various metabolites, either as main effects or as interactions 
with benzene exposure and/or smoking: NQO1*2 for all metabolites, CYP2E1 for all 
metabolites except CA, GSTT1 and GSTM1 for SPMA, EPHX1 (Ex4+52A>G) for SPMA 
and CA, and EPHX1 (Ex3-28T>C) for CA.  Interestingly, variant or deficient alleles of all 
genes [except EPHX1 (Ex4+52A>G)] appeared to be associated with lower levels of benzene 
metabolites relative to homozygous wild alleles. While it was expected that the levels of CA 
and HQ would be lower in subjects with NQO1*2 (less active), lower levels of MA, SPMA, 
and PH among subjects with NQO1*2 seemed to be associated with a more general role for 
NQO1. We also found that NQO1*3 and MPO did not affect metabolism.  As for CYP2E1 (-
1054C>T), significant differences in metabolite levels between homozygous wild-types and 
homozygous variants weres detected at benzene exposures in the range of 0.1 – 2 ppm for 
HQ, PH and MA (Tables 3, 5 and 7 and Fig. 2A). This interaction effect may reflect 
induction of CYP2E1 (-1054C>T) by benzene exposure, or more rapid saturation of 
metabolism among homozygous variant subjects. Our results substantially support evidence 
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from previous studies that CYP2E1 (-1054C>T) mutations functionally reduced the 
metabolism of CYP2E1 substrates. GSTT1 affected the production of SPMA with a clear 
gene-dose relationship. While GSTM1 showed similar effects on SPMA, there was no effect 
of GSTP1 on SPMA. Subjects with variant allele(s) of EPHX1 (Ex3-28T>C) had lower 
levels of CA than homozygous wild-types while those with at least one variant of EPHX1 
(Ex4+52A>G) had marginally higher CA levels, supporting previous in vitro results.  Also, 
differences in CA levels seemed distinguishable between homozygous wild- and variant-
types of EPHX1 (Ex3-28T>C) among smokers exposed to benzene at one ppm or more. It is 
of interest that fast EPHX1 metabolism is a risk factor among smokers.  Although we 
detected many influential SNP effects on benzene metabolites, the portion of SNP effects as 
explanatory variables appeared limited, that is, less than 5% of the total variation of the level 
of any benzene metabolite could be explained by SNPs.  
 
5.2. Implications and Suggestions for Future Research 
In the present study, we observed highly nonlinear relationships with regards to dose-
specific production of benzene metabolites. Considering that MUC and HQ are thought to be 
the most hematotoxic metabolites of benzene (Snyder, 2004), and that metabolism of 
benzene appears to favor these species at lower exposure (Fig. 3.3B, Fig. 3.4) the general 
population might be at higher risk of benzene-induced health effects than generally thought 
from linear extrapolation of risks from studies involving highly exposed subjects.   Also, the 
overall rate of metabolism, expressed as excretion of total benzene metabolites per ppm of 
benzene exposure points to more efficient metabolism at lower exposure (Fig. 3.4F).  Based 
upon the results from the NS basis functions defined in Chapter 2 for total metabolites we 
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estimate that the percentage of the absorbed benzene dose that was excreted as urinary 
metabolites diminished from about 90% at 0.7 ppm, to 56% at 1 ppm, to 46% at 3 ppm. 
These calculations assume a ventilation minute volume of 7.5 l/min (Krishnan and Andersen, 
2001), that 50% of the inhaled benzene is retained (Nomiyama and Nomiyama, 1974), an 8-h 
working day, and a 1 ml/min urine generation rate (Ritschel et al., 1999).  These apparent 
dose-related shifts in benzene metabolism need to be reproduced in other populations.  
Age, gender, and smoking were important explanatory variables for our models of 
urinary benzene metabolites after adjusting for benzene exposure (Chapter 2).  Considering 
that AML tends to be a disease of children and young adults (EPA, 2002), it is possible that 
enhanced benzene metabolism in younger persons might be a risk factor for this disease.  
Also, the fact that females appear to metabolize more benzene than males should also be 
considered as a potential risk factor for leukemia, although rates of AML in the U.S. tend to 
be greater for males than females of all races (Xie et al., 2003).  Finally, since cigarette 
smoke appears to contain significant quantities of benzene, HQ and CA (see Chapter 2), links 
between smoking and leukemia (McDonald et al., 2001) could well reflect exposures to 
benzene and its metabolites. 
We identified relatively small effects of SNPs of metabolizing genes on levels of urinary 
metabolites, which primarily reflect metabolism in liver (Chapter 3). Since liver is not a 
target organ, the roles of SNPs operating in the target blood-forming tissues might be 
different (Lan et al., 2004). Therefore, our results should be considered as reflecting primary 
rates of benzene metabolism and not necessarily as reflecting particular activation and 
deactivation pathways in target cells.  It is important that future studies consider the possible 
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interactions between primary (liver) metabolism and subsequent transformations in target 
tissues to more fully elucidate the mechanism(s) of benzene induced hematotoxic effects. 
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